<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Soc Trans</journal-id><journal-id journal-id-type="iso-abbrev">Biochem. Soc. Trans</journal-id><journal-id journal-id-type="hwp">ppbiost</journal-id><journal-id journal-id-type="publisher-id">BST</journal-id><journal-title-group><journal-title>Biochemical Society Transactions</journal-title></journal-title-group><issn pub-type="ppub">0300-5127</issn><issn pub-type="epub">1470-8752</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6925523</article-id><article-id pub-id-type="publisher-id">BST-47-1757</article-id><article-id pub-id-type="doi">10.1042/BST20190280</article-id><article-categories><subj-group subj-group-type="categories"><subject>Organelles &#x00026; Localization</subject><subject>Cancer</subject><subject>Metabolism</subject><subject>Immunology &#x00026; Inflammation</subject><subject>Bioenergetics</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Articles</subject></subj-group></article-categories><title-group><article-title>Impact of pharmacological agents on mitochondrial function: a growing opportunity?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stoker</surname><given-names>Megan L.</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Newport</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hulit</surname><given-names>James C.</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>West</surname><given-names>A. Phillip</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6926-6550</contrib-id><name><surname>Morten</surname><given-names>Karl J.</given-names></name><xref ref-type="aff" rid="af1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="af1"><label>1</label>NDWRH, The Women's Centre, University of Oxford, Oxford, U.K.</aff><aff id="af2"><label>2</label>Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, U.K.</aff><aff id="af3"><label>3</label>Novintum, London, U.K.</aff><aff id="af4"><label>4</label>Department of Microbial Pathogenesis and Immunology, Texas A&#x00026;M University Health Science Center, Byran, TX, U.S.A.</aff><author-notes><corresp id="cor1">Correspondence: Karl Morten (<email>karl.morten@wrh.ox.ac.uk</email>)</corresp></author-notes><pub-date pub-type="ppub"><day>20</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>7</day><month>11</month><year>2019</year></pub-date><volume>47</volume><issue>6</issue><fpage>1757</fpage><lpage>1772</lpage><history><date date-type="received"><day>23</day><month>8</month><year>2019</year></date><date date-type="rev-recd"><day>9</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s)</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution License 4.0 (CC BY-NC-ND)</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="BST-47-1757.pdf"/><abstract><p>Present-day drug therapies provide clear beneficial effects as many diseases can be driven into remission and the symptoms of others can be efficiently managed; however, the success of many drugs is limited due to both patient non-compliance and adverse off-target or toxicity-induced effects. There is emerging evidence that many of these side effects are caused by drug-induced impairment of mitochondrial function and eventual mitochondrial dysfunction. It is imperative to understand how and why drug-induced side effects occur and how mitochondrial function is affected. In an aging population, age-associated drug toxicity is another key area of focus as the majority of patients on medication are older. Therefore, with an aging population possessing subtle or even more dramatic individual differences in mitochondrial function, there is a growing necessity to identify and understand early on potentially significant drug-associated off-target effects and toxicity issues. This will not only reduce the number of unwanted side effects linked to mitochondrial toxicity but also identify useful mitochondrial-modulating agents. Mechanistically, many successful drug classes including diabetic treatments, antibiotics, chemotherapies and antiviral agents have been linked to mitochondrial targeted effects. This is a growing area, with research to repurpose current medications affecting mitochondrial function being assessed in cancer, the immune system and neurodegenerative disorders including Parkinson's disease. Here, we review the effects that pharmacological agents have on mitochondrial function and explore the opportunities from these effects as potential disease treatments. Our focus will be on cancer treatment and immune modulation.</p></abstract></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Mitochondria are intracellular membrane-bound organelles that act as the cells &#x02018;powerhouse&#x02019; due to their principal function in synthesizing adenosine triphosphate (ATP) required for a multitude of processes and reactions. This is achieved through the coupling of electron transport and the creation of an electrochemical gradient to the synthesis of ATP. The gradient is created by the translocation of protons across the inner membrane to the intermembrane space by three unique oxidoreductases [<xref rid="BST-47-1757C1" ref-type="bibr">1</xref>]. As protons pass back into the mitochondrial matrix via ATP synthase/complex V, this drives the ATP synthase to combine ADP and inorganic phosphate generating the cellular energy fuel ATP (<xref rid="BST-47-1757F1" ref-type="fig">Figure 1</xref>).
<fig id="BST-47-1757F1" orientation="portrait" position="float"><label>Figure&#x000a0;1.</label><caption><title>Key features of mitochondrial structure and function of the ETC.</title><p>Key structures of the mitochondrion are represented in (<bold>A</bold>), while (<bold>B</bold>) depicts the structure of the OXPHOS system and its functioning. Oxidative phosphorylation complexes represent reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase (I), succinate dehydrogenase (II), cytochrome <italic>c</italic> reductase (III), cytochrome <italic>c</italic> oxidase (IV) and ATP synthase (V) where Q represents coenzyme Q and cyt <italic>c</italic> represents cytochrome <italic>c</italic>. In (<bold>B</bold>), black arrows show the transfer of electrons between complexes while red arrows show the transfer of protons throughout the chain for the eventual production of ATP and H<sub>2</sub>O. Features are not to scale.</p></caption><graphic xlink:href="BST-47-1757-g0001"/></fig></p><p>Mitochondria possess their own genome, mitochondrial DNA (mtDNA), which is a 16.6 kbp closed, circular, double-stranded DNA genome. Most cells contain hundreds to thousands of copies of mtDNA, which encodes two ribosomal ribonucleic acid (RNA) and 22 transfer RNAs which are necessary for translation of the 13 mtDNA-encoded mRNAs that comprise key subunits of the oxidative phosphorylation (OXPHOS) complexes [<xref rid="BST-47-1757C2" ref-type="bibr">2</xref>]. Despite the ability of the mitochondria to carry out DNA replication, mtDNA transcription and protein translation independently of the nucleus, these functions are, in fact, semiautonomous in nature [<xref rid="BST-47-1757C3" ref-type="bibr">3</xref>]. Mitochondria require nuclear DNA-encoded genes for function, and indeed, all of the DNA replication, transcription, ribosomal protein machinery and most of the OXPHOS subunits are nuclear encoded [<xref rid="BST-47-1757C4" ref-type="bibr">4</xref>]. Furthermore, anterograde and retrograde signalling between the mtDNA and the nucleus allows mitochondria to change bioenergetics and biosynthetic output to match cellular needs or respond to cellular stress [<xref rid="BST-47-1757C5" ref-type="bibr">5</xref>]. MtDNA contains no introns and histones, and only low levels of repair mechanisms such as mtDNA damage, depletion or mutation may have a very large impact on mitochondrial function. The mtDNA copy number per cell varies greatly with over 150&#x02009;000 in an oocyte to only several hundred in cells found in lung tissue [<xref rid="BST-47-1757C6" ref-type="bibr">6</xref>]. Generally, cells with the highest energy demand have the highest number of mitochondria [<xref rid="BST-47-1757C7" ref-type="bibr">7</xref>] and mtDNA copy number [<xref rid="BST-47-1757C8" ref-type="bibr">8</xref>]. The cellular distribution of mitochondria varies between cell types. Large cells such as motor neurones, being over 1&#x02005;m long, reposition their mitochondria to the site of the neuromuscular junction where the most ATP is required [<xref rid="BST-47-1757C9" ref-type="bibr">9</xref>]. This provides a further complication of moving mitochondria (dynamics) from the cell body along the axon to the synaptic terminals. An inability to maintain mitochondrial function at the synapse potentially leads to neuronal dysfunction and neurodegeneration [<xref rid="BST-47-1757C10" ref-type="bibr">10</xref>] with a disruption in mitochondrial distribution at synaptic/neuromuscular junctions associated with motor neurone diseases such as amyotrophic lateral sclerosis and Huntingdon's disease [<xref rid="BST-47-1757C11" ref-type="bibr">11</xref>,<xref rid="BST-47-1757C12" ref-type="bibr">12</xref>].</p><p>A diverse range of mitochondrial functions have been identified in addition to their crucial role in aerobic respiration and ATP production. Mitochondria dictate cell survival and death via opening of the mitochondrial permeability transition pore [<xref rid="BST-47-1757C13" ref-type="bibr">13</xref>] and play a crucial role in calcium homeostasis and buffering [<xref rid="BST-47-1757C14" ref-type="bibr">14</xref>]. Furthermore, mitochondria have been found to be key players in steroid and hormone signalling, energy sensing, production of reactive oxygen species (ROS) and cofactor synthesis [<xref rid="BST-47-1757C5" ref-type="bibr">5</xref>]. The biosynthesis of critical cofactors is an important role of the organelle including the highly eukaryotic-conserved, formation of iron&#x02013;sulfur clusters and the biosynthesis of haeme, biotin and lipoic acid [<xref rid="BST-47-1757C15" ref-type="bibr">15</xref>]. More recently, it has emerged that mitochondria serve as key immune regulators, shaping both beneficial and detrimental immune responses during pathogen infection, inflammatory diseases, cancer and aging [<xref rid="BST-47-1757C16" ref-type="bibr">16</xref>&#x02013;<xref rid="BST-47-1757C18" ref-type="bibr">18</xref>]. This pivotal role in cell biology explains the severe and multisystem clinical symptoms which occur as a result of mitochondrial dysfunction and highlights the need for increased research on the role of mitochondria in health and disease. To maintain integrity, mitochondria are under strict quality control measures involving fission/fusion [<xref rid="BST-47-1757C19" ref-type="bibr">19</xref>], mitophagy and proteasomal degradation, which can selectively remove both damaged proteins and dysfunctional mitochondria [<xref rid="BST-47-1757C20" ref-type="bibr">20</xref>]. Mitophagy is particularly important in differentiated cells where attempts at modulating it are being explored in order to enhance removal or turnover of damaged mitochondria associated with disease or aging [<xref rid="BST-47-1757C21" ref-type="bibr">21</xref>&#x02013;<xref rid="BST-47-1757C24" ref-type="bibr">24</xref>].</p></sec><sec id="s2"><title>Toxic effects of pharmacological agents on mitochondrial function</title><p>Drug therapy has clear beneficial effects by causing remission of many diseases and improvement in symptom management; however, as patient life expectancy increases, long-term side effects of treatments have emerged. Mitochondrial dysfunction can result from different drug types through a variety of mechanisms, summarized in <xref rid="BST-47-1757TB1" ref-type="table">Table 1</xref>. Antiviral therapy using nucleoside reverse transcriptase inhibitors (NRTIs) can successfully control virus levels, and the development of this antiviral therapy approach proved to be a major cornerstone in reducing the morbidity and mortality of various viral infections such as human immunodeficiency virus (HIV). However, there is a risk of NRTI-induced inhibition of human DNA polymerases due to structural conservation between human and viral polymerases and the disruption of dNTP pools [<xref rid="BST-47-1757C25" ref-type="bibr">25</xref>]. Polymerase inhibition has led to the well-supported &#x02018;DNA pol-&#x003b3; hypothesis&#x02019; of mitochondrial dysfunction, where NRTI treatment inhibits DNA pol-&#x003b3; in mitochondria and results in mtDNA depletion [<xref rid="BST-47-1757C26" ref-type="bibr">26</xref>]. It was found that early HIV treatments had substantial levels of toxicity, such that 25% of patients discontinued their antiviral regime due to the toxicity or from non-compliance [<xref rid="BST-47-1757C27" ref-type="bibr">27</xref>]. Other HIV treatments have been withdrawn completely due to associated mitochondrial toxicity, the antiretroviral drug zalcitibine being a key example [<xref rid="BST-47-1757C28" ref-type="bibr">28</xref>]. The clinical development of new antiviral agents to treat viral infection produced compounds such as tenofovir, which has minimal mitochondrial toxicity compared with zalcitabine and didanosine [<xref rid="BST-47-1757C29" ref-type="bibr">29</xref>]. Tenofovir is used in combination with other NRTI antivirals such as abacavir and lamivudine in modern HIV therapy, all of which report lower mitochondrial toxicity than previous NRTIs [<xref rid="BST-47-1757C30" ref-type="bibr">30</xref>].
<table-wrap id="BST-47-1757TB1" orientation="portrait" position="float"><label>Table&#x000a0;1.</label><caption><title>Summary of drugs with associated mitochondrial toxicity.</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Drug type</th><th align="left" rowspan="1" colspan="1">Examples</th><th align="left" rowspan="1" colspan="1">Mechanism</th><th align="left" rowspan="1" colspan="1">Mitochondrial effects</th><th align="left" rowspan="1" colspan="1">Clinical symptoms</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Antiviral-nuceloside reverse transcriptase inhibitor (NRTI)</td><td rowspan="1" colspan="1">Zidovudine (AZT) (black box warning)<break/>Acyclovir (ACV)<break/>Ganciclovir (GCV)<break/>Zalcitabine (ddC)</td><td rowspan="1" colspan="1">Analogues to endogenous dNTPs therefore inhibit mtDNA polymerase-&#x003b3; and prevent chain elongation of nascent mtDNA chain [<xref rid="BST-47-1757C131" ref-type="bibr">131</xref>,<xref rid="BST-47-1757C132" ref-type="bibr">132</xref>]</td><td rowspan="1" colspan="1">MtDNA depletion [<xref rid="BST-47-1757C26" ref-type="bibr">26</xref>,<xref rid="BST-47-1757C132" ref-type="bibr">132</xref>]<break/>Decreased synthesis of OXPHOS proteins, increased superoxide levels [<xref rid="BST-47-1757C133" ref-type="bibr">133</xref>]<break/>DNA breaks in mtDNA with ACV and GCV [<xref rid="BST-47-1757C134" ref-type="bibr">134</xref>]<break/>Abnormally structured mitochondria [<xref rid="BST-47-1757C135" ref-type="bibr">135</xref>,<xref rid="BST-47-1757C136" ref-type="bibr">136</xref>]<break/>Inhibition of cytochrome <italic>c</italic> oxidase and citrate synthase [<xref rid="BST-47-1757C137" ref-type="bibr">137</xref>]<break/>Interference with the phosphoregulation of ETC subunits [<xref rid="BST-47-1757C26" ref-type="bibr">26</xref>]</td><td rowspan="1" colspan="1">Lactic acidosis, altered lipid metabolism and altered carbohydrate metabolism [<xref rid="BST-47-1757C26" ref-type="bibr">26</xref>]<break/>Red-ragged fibers in muscle, myopathy [<xref rid="BST-47-1757C138" ref-type="bibr">138</xref>,<xref rid="BST-47-1757C139" ref-type="bibr">139</xref>]<break/>Neuropathy, liver steacidosis, pancreatitis [<xref rid="BST-47-1757C29" ref-type="bibr">29</xref>]</td></tr><tr><td rowspan="1" colspan="1">Antiviral-protease inhibitor (PI)</td><td rowspan="1" colspan="1">Saquinavir (black box warning)</td><td rowspan="1" colspan="1">Inhibits cleavage of host cell polyprotiens into functional proteins [<xref rid="BST-47-1757C140" ref-type="bibr">140</xref>]</td><td rowspan="1" colspan="1">Inability to assemble functional ETC [<xref rid="BST-47-1757C26" ref-type="bibr">26</xref>]<break/>Interference with lipid metabolism and retinoid signalling [<xref rid="BST-47-1757C141" ref-type="bibr">141</xref>]</td><td rowspan="1" colspan="1">Lipodystrophy, hyperlipidaemia, insulin resistance [<xref rid="BST-47-1757C141" ref-type="bibr">141</xref>]</td></tr><tr><td rowspan="1" colspan="1">Antibiotic</td><td rowspan="1" colspan="1">Tetracycline</td><td rowspan="1" colspan="1">Inhibition of protein synthesis</td><td rowspan="1" colspan="1">Decreased mitochondrial membrane potential, down-regulation of ETC function and protein synthesis [<xref rid="BST-47-1757C67" ref-type="bibr">67</xref>,<xref rid="BST-47-1757C142" ref-type="bibr">142</xref>]</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ciprofloxacin (black box warning)</td><td rowspan="1" colspan="1">Inhibition of Top2 (topoisomerase) which prevents the relaxation of mtDNA for replication [<xref rid="BST-47-1757C143" ref-type="bibr">143</xref>]</td><td rowspan="1" colspan="1">Inhibition of mtDNA replication, mtDNA depletion and dysregulation of ETC complexes [<xref rid="BST-47-1757C143" ref-type="bibr">143</xref>]<break/>dsDNA breaks [<xref rid="BST-47-1757C144" ref-type="bibr">144</xref>]<break/>Increased ROS levels and oxidative stress [<xref rid="BST-47-1757C145" ref-type="bibr">145</xref>]<break/>Respiration decreased 40% <italic>in vitro</italic>, accompanied by reduced cytochrome <italic>c</italic> oxidase (COX) activity and lactate accumulation [<xref rid="BST-47-1757C146" ref-type="bibr">146</xref>]<break/>Suppression of ETC complexes I and II [<xref rid="BST-47-1757C147" ref-type="bibr">147</xref>]</td><td rowspan="1" colspan="1">Tendinopathies, neuropathies, myopathy and psychological symptoms [<xref rid="BST-47-1757C143" ref-type="bibr">143</xref>]</td></tr><tr><td rowspan="1" colspan="1">Chemotherapy agent</td><td rowspan="1" colspan="1">Cisplatin (black box warning)<break/>Cyclophosphamide</td><td rowspan="1" colspan="1">Bind to the purine residues in the mtDNA of cells to cause damage in the DNA, inhibition of cell division and apoptotic cell death [<xref rid="BST-47-1757C148" ref-type="bibr">148</xref>,<xref rid="BST-47-1757C149" ref-type="bibr">149</xref>]</td><td rowspan="1" colspan="1">Increased ROS production [<xref rid="BST-47-1757C36" ref-type="bibr">36</xref>,<xref rid="BST-47-1757C129" ref-type="bibr">129</xref>]<break/>mtDNA damage in lung and prostate cancer cells [<xref rid="BST-47-1757C150" ref-type="bibr">150</xref>]<break/>Decreased exercise capacity, decreased maximum mitochondrial ATP production [<xref rid="BST-47-1757C151" ref-type="bibr">151</xref>]</td><td rowspan="1" colspan="1">Nephrotoxicity, ototoxicity [<xref rid="BST-47-1757C152" ref-type="bibr">152</xref>]<break/>Peripheral neuropathy [<xref rid="BST-47-1757C129" ref-type="bibr">129</xref>]<break/>Cardiac myopathy [<xref rid="BST-47-1757C36" ref-type="bibr">36</xref>]<break/>Hepatotoxicity [<xref rid="BST-47-1757C78" ref-type="bibr">78</xref>]</td></tr><tr><td rowspan="1" colspan="1">Anti-psychotic</td><td rowspan="1" colspan="1">Clozapine (black box warning)</td><td rowspan="1" colspan="1">Binds serotonin and dopamine receptors with off-target effects on mitochondria [<xref rid="BST-47-1757C153" ref-type="bibr">153</xref>]</td><td rowspan="1" colspan="1">Mitochondrial membrane depolarization, increased inflammatory response, mitochondrial swelling and changes in structure, all which resulted in ATP depletion [<xref rid="BST-47-1757C49" ref-type="bibr">49</xref>]<break/>Oxidation of mitochondrial proteins including malate dehydrogenase and pyruvate kinase [<xref rid="BST-47-1757C50" ref-type="bibr">50</xref>,<xref rid="BST-47-1757C154" ref-type="bibr">154</xref>]</td><td rowspan="1" colspan="1">Obesity, metabolic disturbances and increased diabetes risk [<xref rid="BST-47-1757C50" ref-type="bibr">50</xref>,<xref rid="BST-47-1757C154" ref-type="bibr">154</xref>]<break/>Tardive dyskinesia [<xref rid="BST-47-1757C155" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="1" colspan="1">Antiepileptic</td><td rowspan="1" colspan="1">Sodium valporate (black box warning)</td><td rowspan="1" colspan="1">Acts to increase the concentration of synaptic GABA with off-target effects on mitochondria [<xref rid="BST-47-1757C156" ref-type="bibr">156</xref>]</td><td rowspan="1" colspan="1">Decreased membrane potential, ATP depletion, increased cell death and reduction in cell number [<xref rid="BST-47-1757C51" ref-type="bibr">51</xref>]<break/>Inhibition of the PDH complex [<xref rid="BST-47-1757C52" ref-type="bibr">52</xref>]<break/>Sequestration of free acetyls CoA [<xref rid="BST-47-1757C157" ref-type="bibr">157</xref>]</td><td rowspan="1" colspan="1">Hepatotoxicity [<xref rid="BST-47-1757C51" ref-type="bibr">51</xref>,<xref rid="BST-47-1757C52" ref-type="bibr">52</xref>,<xref rid="BST-47-1757C157" ref-type="bibr">157</xref>]<break/>Metabolic disturbances [<xref rid="BST-47-1757C52" ref-type="bibr">52</xref>]<break/>Foetal anticonvulsant syndrome [<xref rid="BST-47-1757C53" ref-type="bibr">53</xref>]</td></tr><tr><td rowspan="1" colspan="1">Antidepressant-selective serotonin reuptake inhibitor (SSRI)</td><td rowspan="1" colspan="1">Sertraline<break/>Fluoxetine (black box warning)</td><td rowspan="1" colspan="1">Acts to increase the concentration of serotonin by blocking reabsorption with off-target effects on mitochondria [<xref rid="BST-47-1757C158" ref-type="bibr">158</xref>]</td><td rowspan="1" colspan="1">OXPHOS inhibited in isolated rat brain and liver mitochondria [<xref rid="BST-47-1757C159" ref-type="bibr">159</xref>,<xref rid="BST-47-1757C160" ref-type="bibr">160</xref>]<break/>Reduced mitochondrial biogenesis [<xref rid="BST-47-1757C161" ref-type="bibr">161</xref>]<break/>Ion compartmentalization [<xref rid="BST-47-1757C162" ref-type="bibr">162</xref>]<break/>Change in morphology to more rounded and shrivelled, indicative of increased caspase 3 activity [<xref rid="BST-47-1757C163" ref-type="bibr">163</xref>]<break/>Decreased respiratory activity [<xref rid="BST-47-1757C164" ref-type="bibr">164</xref>]<break/>Inhibition of complexes I, III and IV in the ETC [<xref rid="BST-47-1757C163" ref-type="bibr">163</xref>]<break/>Down-regulation of ETC proteins [<xref rid="BST-47-1757C165" ref-type="bibr">165</xref>]</td><td rowspan="1" colspan="1">Hyponatremia, weight gain [<xref rid="BST-47-1757C166" ref-type="bibr">166</xref>]</td></tr></tbody></table></table-wrap></p><p>Mitochondrial toxicity is also associated with other drug classes with responses being significantly influenced by patient&#x02013;patient variability in mitochondrial function. Mitochondrial toxicity is also associated with other drug classes, with the effects being significantly influenced by differences in mitochondrial function caused by patient&#x02013;patient variability. Patients with diagnosed mitochondrial disorders, in particular those carrying A1555G and C1494T mutations in human mitochondrial 12S rRNA, are acutely sensitive to aminoglycoside antibiotics, which can result in deafness [<xref rid="BST-47-1757C31" ref-type="bibr">31</xref>]. Age-related deafness (presbyacusis) is extremely common in western societies affecting half of all people over 75 years of age. An impact on mitochondrial function by many common medications on age-related deafness cannot be ruled out [<xref rid="BST-47-1757C32" ref-type="bibr">32</xref>]. Since the 1920s, cardiovascular diseases have been the leading cause of death globally (World Health Organization). Statins which lower lipid levels, illness and mortality for individuals at high risk have become the most commonly prescribed drug class in the world. However, like other drugs, these are also associated with mitochondrial toxicity [<xref rid="BST-47-1757C33" ref-type="bibr">33</xref>]. Recent studies have shown the presence of mitochondrial-induced myopathies brought on through reduced respiratory enzyme activity, calcium leakage and ROS-induced oxidative stress in patients being treated with statins [<xref rid="BST-47-1757C34" ref-type="bibr">34</xref>,<xref rid="BST-47-1757C35" ref-type="bibr">35</xref>]. The reported incidence varies between 5% and 30% with the milder disease being more common than the very rare rhabdomyolysis reported at 1 in 10&#x02009;000 patients. Chemotherapeutic agents are renowned for adverse side effects. Drugs must be potent in order to combat the highly resistant cancer cells; however, many chemotherapy agents cause the generation of excessive ROS, which results in oxidative stress and mitochondrial damage [<xref rid="BST-47-1757C36" ref-type="bibr">36</xref>]. Although this affect limits the efficacious potential of these agents, mitochondrial signalling pathways associated with ROS are essential for cellular function and are linked to various processes including the activity of phosphatases [<xref rid="BST-47-1757C37" ref-type="bibr">37</xref>], mitochondria perinuclear clustering [<xref rid="BST-47-1757C38" ref-type="bibr">38</xref>] and longevity at the level of the whole organism in <italic>Caenorhabditis elegans</italic> [<xref rid="BST-47-1757C39" ref-type="bibr">39</xref>]. In <italic>C. elegans</italic>, reduced glucose availability leads to increase mitochondrial respiration and mitochondrial ROS (mtROS) production that actually delays worm aging [<xref rid="BST-47-1757C40" ref-type="bibr">40</xref>]. Control over mtROS signalling is an exciting new area of research which presents opportunities to regulate appetite and food intake by the actions of uncoupling protein 2 (UCP2) in the brain (reviewed in [<xref rid="BST-47-1757C41" ref-type="bibr">41</xref>]). UCP2 likely controls mtROS indirectly via alteration of mitochondrial fuel utilization [<xref rid="BST-47-1757C42" ref-type="bibr">42</xref>,<xref rid="BST-47-1757C43" ref-type="bibr">43</xref>]. Pharmacological regulation of mtROS will be an important area in the future with opportunities to regulate many cellular pathways including wound healing [<xref rid="BST-47-1757C44" ref-type="bibr">44</xref>], survival under hypoxia [<xref rid="BST-47-1757C45" ref-type="bibr">45</xref>], intracellular pH homeostasis [<xref rid="BST-47-1757C46" ref-type="bibr">46</xref>], innate immunity [<xref rid="BST-47-1757C47" ref-type="bibr">47</xref>] and cell differentiation [<xref rid="BST-47-1757C48" ref-type="bibr">48</xref>].</p><p>Mitochondrial off-target effects are also observed with anti-psychotic drugs. Anti-psychotic drugs became the standard of care for psychiatric disorders such as schizophrenia and mood disorders in the 1950s with the development of chlorpromazine, the first anti-psychotic. However, adverse effects originating from the mitochondria soon became apparent as metabolic disturbances caused by mitochondrial membrane depolarization and swelling were observed [<xref rid="BST-47-1757C49" ref-type="bibr">49</xref>,<xref rid="BST-47-1757C50" ref-type="bibr">50</xref>]. The epileptic drug sodium valproate has well documented mitochondrial toxicity showing respiratory dysfunction <italic>in vitro</italic> in HEPG2 cells [<xref rid="BST-47-1757C51" ref-type="bibr">51</xref>] and <italic>in vivo</italic> where valproate-induced mitochondrial dysfunction has been associated with hepatotoxicity [<xref rid="BST-47-1757C52" ref-type="bibr">52</xref>] and foetal anticonvulsant syndrome [<xref rid="BST-47-1757C53" ref-type="bibr">53</xref>]. Mitochondrial linked organ toxicities are the commonest reason for licensed medicines to be given black warnings [<xref rid="BST-47-1757C54" ref-type="bibr">54</xref>].</p><p>Patient-to-patient variation in treatment benefits and adverse toxicity is potentially linked to the variation in mitochondrial function found between individuals and declines with aging as it is also influenced by cell type, gender, state of immunity, and number and severity of pathogenic infections [<xref rid="BST-47-1757C55" ref-type="bibr">55</xref>,<xref rid="BST-47-1757C56" ref-type="bibr">56</xref>]. Mitochondria become larger, less numerous and less efficient with age as continuous ROS-associated protein, lipid and nucleic acid damage result in an increase in mitochondrial dysfunction over time [<xref rid="BST-47-1757C5" ref-type="bibr">5</xref>]. Furthermore, mitochondrial quality control also deteriorates with aging as is observed in the decline of mitophagy in age-related pathologies such as Alzheimer's disease and Parkinson's disease (PD) [<xref rid="BST-47-1757C57" ref-type="bibr">57</xref>]. The result of this decline is a decreased ability to remove damaged mitochondria and ultimately leads to the accumulation of dysfunctional mitochondria [<xref rid="BST-47-1757C58" ref-type="bibr">58</xref>].</p><p>Genetics also influences susceptibility to mitochondrial and metabolic dysfunction. For example, the mtDNA genetic variant at 16&#x02009;189 from T to C has been associated with increased oxidative damage, altered antioxidant status and onset of type two diabetes [<xref rid="BST-47-1757C59" ref-type="bibr">59</xref>&#x02013;<xref rid="BST-47-1757C61" ref-type="bibr">61</xref>]. Furthermore, different mtDNA haplogroups have been increasingly associated with individual susceptibility to toxic side effects observed in some patients [<xref rid="BST-47-1757C62" ref-type="bibr">62</xref>&#x02013;<xref rid="BST-47-1757C66" ref-type="bibr">66</xref>]. Haplogroups, distinct patterns in single-nucleotide polymorphisms (SNPs) in mtDNA, naturally arise from human evolution and have been shown to result in different bioenergetic capacities, ROS production and apoptotic capabilities [<xref rid="BST-47-1757C64" ref-type="bibr">64</xref>]. With these different haplogroups influencing mitochondrial function, it has since been shown that specific haplogroups increase susceptibility to toxic side effects of drug use; for example, the 4917G allele in patients with haplogroup T and the subhaplo group L02a are associated with NRTI-induced peripheral neuropathy [<xref rid="BST-47-1757C64" ref-type="bibr">64</xref>,<xref rid="BST-47-1757C65" ref-type="bibr">65</xref>]. The accumulation of SNPs in mtDNA, combined with the use of drugs that affect mitochondrial function, is therefore a major determinant in the development of idiosyncratic drug-induced adverse effects [<xref rid="BST-47-1757C63" ref-type="bibr">63</xref>].</p></sec><sec id="s3"><title>Opportunities in disease treatment using mitochondrial drug-induced effects</title><p>As suggested above, screening drugs for adverse toxicity against mitochondria is vital for their safe use. However, many drugs have been discovered with interesting modulating properties that potentially could prove useful in the clinic or as research tools. The concern in the pharmaceutical industry to screen out drugs with dangerous adverse side effects may have led to the rejection of many beneficial drugs. Research has revealed over the past decade a dependency of many cancer types on mitochondrial function. These dependencies can be shown to be a liability in some cases as selective targeting of the mitochondria has proved efficacious in these studies. Potentially useful new therapeutic cancer agents such as the common antibiotic doxycycline with only mild mitochondrial effects [<xref rid="BST-47-1757C67" ref-type="bibr">67</xref>,<xref rid="BST-47-1757C68" ref-type="bibr">68</xref>] might have been discarded at the initial drug-screening phase if put through these. The benefit of drug-targeting mitochondria is particularly relevant to the treatment of cancer. Recent research has demonstrated that cancer cells have a strong reliance on mitochondrial function particularly in the area of metastatic disease [<xref rid="BST-47-1757C69" ref-type="bibr">69</xref>&#x02013;<xref rid="BST-47-1757C72" ref-type="bibr">72</xref>]. The new cancer drug ONC201 [<xref rid="BST-47-1757C73" ref-type="bibr">73</xref>], which has demonstrated efficacy in cell culture and animal models, is currently being tested against multiple cancer types and could have been discarded if put through a mitochondrial toxicity screen. ONC201 was identified from a screen for compounds that induced the transcription of tumour necrosis-related apoptosis-inducing ligand (TRAIL), an inducer of apoptosis [<xref rid="BST-47-1757C74" ref-type="bibr">74</xref>]. Follow-up studies discovered that ONC201 did not directly activate TRAIL in all of the cancer cells in which it was effective but was impairing mitochondrial function [<xref rid="BST-47-1757C75" ref-type="bibr">75</xref>]. Recent data from two studies identified the target of ONC201 as being the mitochondrial CLPP protease which is activated by ONC201 and results in increased cancer cell killing [<xref rid="BST-47-1757C76" ref-type="bibr">76</xref>,<xref rid="BST-47-1757C77" ref-type="bibr">77</xref>].</p><p>There exists a range of disorders which could potentially benefit from (i) therapeutic-targeting of dysfunctional mitochondria, (ii) modulation of mitochondrial metabolism or (iii) the delivery of antioxidants to reduce oxidative stress-induced damage [<xref rid="BST-47-1757C78" ref-type="bibr">78</xref>]. The treatments of epilepsy and pyruvate dehydrogenase (PDH) deficiency are good examples of the therapeutic benefits of modulating mitochondrial metabolism, where dietary alterations to a ketogenic diet cause increased fatty acid utilization and alleviation of symptoms [<xref rid="BST-47-1757C79" ref-type="bibr">79</xref>,<xref rid="BST-47-1757C80" ref-type="bibr">80</xref>]. Metabolic hormesis is another growing area of interest and is defined by mitochondrial inhibitory agents causing a positive effect on mitochondria when in a low dose range [<xref rid="BST-47-1757C81" ref-type="bibr">81</xref>]. The general concept related to mitochondrial function is that a little of what is bad for you does you good, analogous to red wine in small doses being beneficial [<xref rid="BST-47-1757C82" ref-type="bibr">82</xref>]. The idea of metabolic hormesis is demonstrated in <xref rid="BST-47-1757F2" ref-type="fig">Figure 2</xref> where two drugs bithionol and meclizine are added to Ewings sarcoma cancer cell lines. This is an effect we observed with many drugs emphasizing the potential of increasing mitochondrial function at low drug doses. At each glucose condition tested, bithionol and meclizine at higher doses inhibit oxygen consumption (i.e. little change in fluorescence lifetime over time). However, at low drug doses, respiration can be enhanced and the response is shown to vary with both glucose level and cell type. This is an effect we observed with many drugs emphasizing the potential of increasing mitochondrial function at low drug doses. In agreement with this data, meclizine inhibits mitochondrial respiration <italic>in vitro</italic> but has also shown to provide neuroprotective effects against PD and Huntingdon's models [<xref rid="BST-47-1757C83" ref-type="bibr">83</xref>&#x02013;<xref rid="BST-47-1757C85" ref-type="bibr">85</xref>].
<fig id="BST-47-1757F2" orientation="portrait" position="float"><label>Figure&#x000a0;2.</label><caption><title>Oxygen consumption of Ewing sarcoma in the presence of Bithionol or Meclizine.</title><p>Ewing sarcoma cell lines TC71 and A673 were seeded at 50k cells/well (with and without treatment) in an oil-layered sealed system under varying glucose levels. Fluorescence lifetime was monitored using an oxygen sensing probe (MitoXpress Xtra, Agilent [<xref rid="BST-47-1757C73" ref-type="bibr">73</xref>]). Vertical axis indicates fluorescent lifetime levels in microseconds with increases, indicating higher oxygen consumption (lower media levels). Horizontal axis indicates time in hours.</p></caption><graphic xlink:href="BST-47-1757-g0002"/></fig></p></sec><sec id="s4"><title>Mitochondrial targeting to treat cancer</title><p>In 2018, 17 million new cases of cancer were reported worldwide with 9.6 million deaths from the disease [<xref rid="BST-47-1757C86" ref-type="bibr">86</xref>]. Targeting malignancy and therapy resistance are the major obstacles limiting current treatment strategies. Otto Warburg was the first to suggest mitochondrial involvement in the disease upon the observation that malignant cells have elevated uptake of glucose, which undergoes fermentation to lactate even in the presence of oxygen. This indicates a metabolic switch from OXPHOS to aerobic glycolysis, later named the &#x02018;Warburg effect&#x02019; [<xref rid="BST-47-1757C87" ref-type="bibr">87</xref>], and fuelled the hypothesis that mitochondrial dysfunction was the cause of tumour progression. Positron-emission tomography imaging, which monitors tumour glucose utilization, is the main clinical approach to determine in a non-invasive manner, treatment effectiveness and tumour recurrence [<xref rid="BST-47-1757C88" ref-type="bibr">88</xref>]. The glucose signature was believed to reflect the glycolytic nature of the tumour; however, recent evidence suggests that this may not be the case, as functional mitochondria are essential for malignant cell survival and oncogenesis [<xref rid="BST-47-1757C89" ref-type="bibr">89</xref>]. This was highlighted by reduced tumour growth and progression in mice when cancer cells are made mtDNA deficient (&#x003c1;0) or when the mtDNA transcription factor A is knocked out causing mtDNA depletion [<xref rid="BST-47-1757C90" ref-type="bibr">90</xref>]. Other data suggest that mtDNA mutations in cancer are not linked to the development or spread and that cancer cells require the presence of active mitochondria to survive [<xref rid="BST-47-1757C91" ref-type="bibr">91</xref>]. Targeting cancer mitochondrial function is an exciting area with new drugs identified and several drugs (Metformin; IM156 Immuniomet; IACS10759 MD Anderson CC; AG-636 Agios; CPI-839; CB-839 Calithera) currently being tested in clinical trials across a wide range of tumour types [<xref rid="BST-47-1757C92" ref-type="bibr">92</xref>&#x02013;<xref rid="BST-47-1757C94" ref-type="bibr">94</xref>]. Mitochondrial targeted drugs are presently being explored in combination with chemotherapy [<xref rid="BST-47-1757C95" ref-type="bibr">95</xref>,<xref rid="BST-47-1757C96" ref-type="bibr">96</xref>] and radiotherapy [<xref rid="BST-47-1757C97" ref-type="bibr">97</xref>]. These combinatorial studies will most likely extend to immunomodulatory agents in the near future.</p><p>An increasing number of studies addressing the phenomenon of cancer cell and metabolic-reprogramming conclude the essential nature of the switching for both cell survival and resistance to anticancer therapies [<xref rid="BST-47-1757C70" ref-type="bibr">70</xref>,<xref rid="BST-47-1757C98" ref-type="bibr">98</xref>,<xref rid="BST-47-1757C99" ref-type="bibr">99</xref>]. Metabolic switching between OXPHOS, glycolysis, fatty acid oxidation and other carbon sources for energy and biosynthetic needs allows adaptation to drastic changes in the tumour microenvironment [<xref rid="BST-47-1757C100" ref-type="bibr">100</xref>]. These bioenergetic adaptations depend greatly on mitochondrial function. Complex I's role in the glycolytic switch is one example as it has been found to be essential in several tumour types [<xref rid="BST-47-1757C101" ref-type="bibr">101</xref>,<xref rid="BST-47-1757C102" ref-type="bibr">102</xref>]. The anticancer BRAF inhibitor vemurafenib switches cellular metabolism from glycolysis to OXPHOS. This drug, coupled with an electron transport chain (ETC) inhibitor such as honokiol, decreases drug resistance and has activity <italic>in vivo</italic> against vemurafenib-resistant melanoma [<xref rid="BST-47-1757C103" ref-type="bibr">103</xref>]. Therefore, combinatorial treatments utilizing both OXPHOS and glycolytic inhibitors provide exciting new therapeutic opportunities [<xref rid="BST-47-1757C70" ref-type="bibr">70</xref>].</p><p>Mitochondrial reprogramming in tumour progression extends beyond changes in mitochondrial bioenergetics. Tumour metastasis, a process implicated in 90% of cancer deaths, is also dictated by changes in mitochondrial function and distribution [<xref rid="BST-47-1757C104" ref-type="bibr">104</xref>]. Agarwal et al. [<xref rid="BST-47-1757C105" ref-type="bibr">105</xref>] demonstrated that the exploitation of mitochondrial trafficking is a key hallmark of myc-driven tumour progression, where subcellular mitochondrial trafficking to the cortical cytoskeleton is vital for tumour cell invasion and metastasis. Myc proteins are products of oncogenes, often amplified in human cancers, which promote tumour growth and progression. They have been associated with the control of the gene network of mitochondrial trafficking and changes in the expression of OXPHOS genes and bioenergetics pathways [<xref rid="BST-47-1757C105" ref-type="bibr">105</xref>]. Mitochondrial trafficking and redistribution is a vital and standard process in healthy neurones, where mitochondria are repositioned to axon terminals to fuel highly energy-intensive processes such as synaptic functions and active growth cones [<xref rid="BST-47-1757C106" ref-type="bibr">106</xref>]; however, the same protein network is exploited by tumour cells to propel metastasis [<xref rid="BST-47-1757C107" ref-type="bibr">107</xref>]. The importance of mitochondrial trafficking in myc-driven tumours is further highlighted by the up-regulation of RHOT2, a mitochondrial atypical GTPase [<xref rid="BST-47-1757C107" ref-type="bibr">107</xref>], and the down-regulation of syntaphilin (SNPH), an inhibitor of mitochondrial trafficking [<xref rid="BST-47-1757C108" ref-type="bibr">108</xref>] in tumour progression. This recent evidence demonstrates the involvement of mitochondrial dynamics in tumour progression; therefore, the inhibition of myc proteins through doxycycline use, or drug-induced modulation of mitochondrial dynamics may have therapeutic benefit.</p><p>Oxidative stress is a hallmark of cancer cells as elevated ROS activates signalling pathways such as the epidermal growth factor receptor and mitogen-activated protein kinase which promote cell growth and proliferation [<xref rid="BST-47-1757C100" ref-type="bibr">100</xref>,<xref rid="BST-47-1757C109" ref-type="bibr">109</xref>]. Antioxidant systems in cells, such as the thioredoxin and glutathione system, allow cells to cope with excessive ROS production in both malignant and healthy cells [<xref rid="BST-47-1757C96" ref-type="bibr">96</xref>]. Elevated ROS in cancer cells is what differentiates malignant cells from healthy cells. Thus, it is thought that the inhibition of antioxidant systems in cancer cells would cause an overload of ROS-induced damage leading to apoptosis in cancer cells only. NSC130362, a small molecule glutathione inhibitor, is one such treatment developed to test this hypothesis. NSC130362 suppressed growth of cancer cell lines and hindered tumour growth <italic>in vivo</italic>, but did not affect the viability of primary human hepatocytes [<xref rid="BST-47-1757C110" ref-type="bibr">110</xref>]. Furthermore, the molecule sensitized <italic>ex vivo</italic> leukaemia cells to other anticancer drugs and potentiated their cytotoxic effects [<xref rid="BST-47-1757C96" ref-type="bibr">96</xref>]. These results suggest that the induction of additional oxidative stress in tumour cells may provide a therapeutic benefit. Furthermore, using potent antivirals or antibiotics which possess off-target ROS-producing effects in the mitochondria, for example doxorubicin, may cause the accumulation of ROS beyond the antioxidant capacity of malignant cells and result in apoptosis [<xref rid="BST-47-1757C111" ref-type="bibr">111</xref>&#x02013;<xref rid="BST-47-1757C113" ref-type="bibr">113</xref>]. These drugs will induce oxidative stress in healthy cells also; however, the malignant cells already have elevated ROS such that the additional levels will exceed a critical threshold, while healthy cells will survive as oxidative stress is low.</p><p>Epigenetic dysregulation is a feature of almost all human cancers [<xref rid="BST-47-1757C114" ref-type="bibr">114</xref>], and while ROS is a well-known genotoxin at excess levels, other mitochondrial metabolites have also proved to be oncogenic [<xref rid="BST-47-1757C100" ref-type="bibr">100</xref>]. The tricarboxylic acid cycle metabolites such as succinate, fumarate and 2-hydroxyglutarate all inhibit &#x003b1;-ketoglutarate-dependent enzymes and interfere with their control over epigenetic regulation. Importantly, the result of this interference leads to post-translational protein modifications and the activation of oncogenic transcription factors. These include Jumonji domain histone lysine demethylases, stabilization of hypoxia-inducible factor A and succination of kelch-like ECH-associated protein 1 activating the oncogenic nuclear factor erythroid 2-related protein 2 [<xref rid="BST-47-1757C100" ref-type="bibr">100</xref>]. Efficient mitochondrial function is dependent on optimal mitochondrial ribosomal translation and assembly of the oxidative phosphorylation complexes. Topoisomerases, which are required for efficient DNA replication and RNA transcription, also play a crucial role in the tumorigenic process. Mitochondrial topoisomerase IB (TOP1MT) is a nuclear encoded, exclusively mitochondrial localized enzyme which is found overexpressed in some tumour types. Baechler et al. [<xref rid="BST-47-1757C115" ref-type="bibr">115</xref>] showed that HCT116 colon cancer cells had decreased tumour growth and cell proliferation in TOP1MT knockout models, therefore providing further proof of the importance of mitochondrial function in cancer progression.</p><p>In summary, many mitochondrial-specific, drug-induced adverse effects have proved useful in reducing tumour growth and sensitizing tumour cells to standard of care therapies. This is due to modulation of mitochondrial metabolism, induction of ROS-mediated apoptosis and regulation of the mitochondrial-induced cell death pathways through mitochondrial outer membrane permeabilization (MOMP) and mitochondrial permeability transition. Therapeutic selectivity remains a main concern when using drugs with mitochondrial toxicity as they have the potential to induce severe and unpleasant clinical symptoms if healthy cells are affected.</p></sec><sec id="s5"><title>Modulation of the innate immune system by mitochondrial manipulation</title><p>Mitochondria also play an important role in the immune response such as during activation of the innate response and through direct stimulation of specific pathways. Pathogen clearance relies heavily on various signalling cascades involved in the maturation, expansion and functioning of immune cells. As these processes require significant amounts of energy, it is not surprising that mitochondria are involved in the innate immune system through their role in cellular bioenergetics and signalling. An important signalling role of mitochondria has already been well established, for example during key steps of apoptosis and autophagy mediated through the generation of ROS and the regulation of calcium [<xref rid="BST-47-1757C116" ref-type="bibr">116</xref>]. Mitochondria exert their modulatory effects on the innate immune system primarily through various cell-signalling events, usually activated on the entry of pathogenic RNA, dsDNA and dsRNA into the cell. In addition, a recent paper by Dhir et al. [<xref rid="BST-47-1757C117" ref-type="bibr">117</xref>] showed that mitochondrial derived dsRNA can induce antiviral signalling by triggering a type I interferon response. In both the innate and adaptive immune systems, rewiring of mitochondrial function is required for optimal function of both phagocytic cells and lymphocytes. Indeed, naive T-cells must switch from a metabolically quiescent to a metabolically active state in order to become fully activated. This increased metabolic activity is achieved through enhanced mitochondrial metabolism and indicates that the important role the organelle plays in the immune response [<xref rid="BST-47-1757C118" ref-type="bibr">118</xref>].</p><p>Furthermore, defective mitochondria can activate immune responses through a variety of different mechanisms (<xref rid="BST-47-1757F3" ref-type="fig">Figure 3</xref>). The cytosolic release of mtDNA can exert potent immunostimulatory effects. Mitochondrial dysfunction or MOMP caused by pathogenic infection or toxic drugs can result in the release of mtDNA [<xref rid="BST-47-1757C106" ref-type="bibr">106</xref>,<xref rid="BST-47-1757C107" ref-type="bibr">107</xref>], which acts as a damage-associated molecular pattern and engages with pattern recognition receptors (PRRs) [<xref rid="BST-47-1757C108" ref-type="bibr">108</xref>] to activate immune responses. The predominant immunomodulatory action of cytosolic mtDNA is through the activation of the STING pathway, a critical antiviral regulatory system activated by viral dsDNA during infection [<xref rid="BST-47-1757C118" ref-type="bibr">118</xref>]. During an infection, viral pathogens can cause mitochondrial dysfunction within infected cells. This is achieved by viral interference with mitochondrial signalling pathways and dynamics to favour viral proliferation and commonly occurs through the inhibition of apoptosis or the innate immune response [<xref rid="BST-47-1757C119" ref-type="bibr">119</xref>]. The pathogen-induced dysfunction increases the production of ROS or the release of mtDNA, where both may act as mediators for the STING pathway [<xref rid="BST-47-1757C120" ref-type="bibr">120</xref>]. The activation of the STING pathway leads to increased expression of IRF3, IRF7 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF&#x003ba;B) transcription factors that control the expression of type I interferons (IFN-I) and interferon-stimulated genes, which directly restrict viral replication [<xref rid="BST-47-1757C16" ref-type="bibr">16</xref>,<xref rid="BST-47-1757C57" ref-type="bibr">57</xref>,<xref rid="BST-47-1757C121" ref-type="bibr">121</xref>]. Drugs which induce mtDNA release or enhance ROS may therefore mimic this effect and lead to up-regulation of antiviral pathways independent of infection, making them useful for both priming the innate immune system or for increasing the efficiency of viral clearance. mtDNA also contains a regulatory D-loop which allows it to act as a ligand for PRRs causing the activation of immune responses [<xref rid="BST-47-1757C57" ref-type="bibr">57</xref>,<xref rid="BST-47-1757C118" ref-type="bibr">118</xref>,<xref rid="BST-47-1757C122" ref-type="bibr">122</xref>]. In endosomal vesicles, this orchestrates signalling through Toll-like receptor 9 (TLR9) for the activation of both pro-inflammatory and antiviral effector responses in a variety of human immune cells [<xref rid="BST-47-1757C123" ref-type="bibr">123</xref>]. TLR9 is also expressed on the outer surface of cells, allowing free mtDNA present in extracellular fluid to also activate the pathway. Similar to the STING pathway, TLR9 signalling can also activate IRF7 and NF&#x003ba;B transcription factors. Among the inflammatory cytokine proteins up-regulated are TNF-&#x003b1; (tumour necrosis factor alpha) and IFN-I (interferon type I) which increase both pro-inflammatory and antiviral responses.
<fig id="BST-47-1757F3" orientation="portrait" position="float"><label>Figure&#x000a0;3.</label><caption><title>Cellular signalling pathways in response to pathogenic viral infection or mtDNA release.</title><p>Antiviral pathways can be stimulated by both RNA and dsDNA from receptor-mediated fusion events or endocytosis. These foreign nucleic acids interact with pattern recognition receptors, such as RIG-I like receptors (RLRs), or with cGAS (cyclic GMP-AMP synthase) which initiates the STING (Stimulator of Interferon Genes) antiviral response pathway. mtDNA acts as a ligand for many immune receptors so is capable of activating both cGAS and RLRs as well as the NLRP3 (nod-like receptor family pyrin domain containing 3) inflammasome for the up-regulation of cytokine release and a pro-inflammatory response.</p></caption><graphic xlink:href="BST-47-1757-g0003"/></fig></p><p>The activation of the NLRP3 inflammasome is also a key pathway in mtDNA-dependent immune responses. Oxidized mtDNA is able to directly bind to the inflammasome to induce IL-1&#x003b2; production [<xref rid="BST-47-1757C124" ref-type="bibr">124</xref>]. Furthermore, ROS from dysfunctional mitochondria are also potent activators of the inflammasome. This was demonstrated <italic>in vitro</italic> as rotenone and antimycin A treatments produced both increased mtROS levels and NLRP3 inflammasome activity [<xref rid="BST-47-1757C125" ref-type="bibr">125</xref>&#x02013;<xref rid="BST-47-1757C127" ref-type="bibr">127</xref>]. The activation of the inflammasome causes cleavage-mediated release of caspase-1 from procaspase-1 resulting in the activation of IL-1B and IL-18, which contribute to an increased pro-inflammatory response. Induction of mild-to-moderate mitochondrial dysfunction through drug therapy could increase cytosolic mtDNA and ROS production from impaired ETC function. These changes could potentially enhance the activation of TLR9, STING and NLRP3 inflammasome-regulated pathways causing increased inflammatory responses and potentially more efficient pathogen and infection clearance. However, care must be taken if using drug therapy to enhance an immune response as there exist a chance of initiating a pro-inflammatory state.</p><p>As just described, recent studies have revealed an important role for mitochondria in the immune response. There is much to understand in this emerging field as the specific functional role that mitochondria assume is immune cell specific. Because these roles manifest themselves through different forms such as enhanced/reduced ROS or altered mtDNA copy number-modulation of mitochondrial morphology, a variety of opportunities are thus presented for drug manipulation of mitochondria. Manipulating mtROS production, for example, has the potential to drive an increased immune response through both increased innate immune signalling and increased release of mtDNA for PRR stimulation. Up-regulating immune activation via altering bioenergetics or increasing mtDNA release/sensing could be beneficial not only in clearing both viral and bacterial infections, but also be effective tools in engaging the immune system to destroy cancer cells. Indeed, several drugs that increase STING activation are being developed or are in clinical trials for cancer therapy. These drugs perhaps may be paired with other chemotherapeutics that cause mitochondrial dysfunction, leading to the increased sensing of mtDNA and other mitochondrial ligands to augment anti-tumour immunity at both the innate and adaptive levels. On the contrary, long-term drug-induced mtDNA depletion has been shown to inhibit interferon and PRR-mediated signalling and therefore can blunt innate immune responses [<xref rid="BST-47-1757C128" ref-type="bibr">128</xref>]. Therapeutics that down modulate mitochondrial function in immune cells may be beneficial in diseases where hyper-activation of the immune system causes life-threatening symptoms, such as autoimmunity and sepsis. Thus, future research into compounds that dampen mitochondrial function or improve mitochondrial quality control may yield new therapies for a wide array of immunological and inflammatory disorders.</p></sec><sec sec-type="conclusions" id="s6"><title>Conclusions</title><p>Much of the evidence to date indicates that a variety of drugs, particularly antivirals and chemotherapy agents, are capable of inducing mitochondrial dysfunction through mtDNA depletion, increased ROS production and uncoupled OXPHOS [<xref rid="BST-47-1757C26" ref-type="bibr">26</xref>,<xref rid="BST-47-1757C129" ref-type="bibr">129</xref>,<xref rid="BST-47-1757C130" ref-type="bibr">130</xref>]. Mitochondrial dysfunction results from off-target effects from these drugs rather than being the main mode of action; however, we have shown that modulating mitochondrial function could be beneficial in the treatment of a variety of diseases such as cancer, diabetes and chronic viral infection. This can be achieved through alterations in mtDNA biogenesis, metabolic rewiring and up-regulation of the immune system. The great challenge to achieve beneficial effects will selectivity and how to maintain mitochondrial outputs in normal healthy tissue while modulating mitochondrial function, or pathogen levels in target tissues.</p><boxed-text position="float" orientation="portrait"><sec><title>Perspectives</title><list list-type="bullet"><list-item><p><bold>Importance of the field:</bold> Understanding the mechanisms of drug-induced mitochondrial toxicity is a highly important field for the development of new therapeutic agents with lower toxicity, as this is vital for patient safety and the development of successful therapeutics. Exploring opportunities of the off-target effects of current drugs is just as vital. Advancements in disease treatment in the last century have left few new drug targets available; therefore, rethinking new uses for the current drugs available is crucial.</p></list-item><list-item><p><bold>Current thinking:</bold> Overall, we believe that there is considerable evidence that current drugs carrying black box warnings of mitochondrial toxicity are a growing opportunity. Drugs indirectly affecting mitochondria have been recently used as a main mode of action to treat diseases such as type 2 diabetes and cancer, as well as up-regulating the immune system to clear infection with promising success; however, considerable caution must be taken when inducing mitochondrial dysfunction for disease treatment because of the vital dependency normal cells have on mitochondrial function.</p></list-item><list-item><p><bold>Future direction:</bold> Presently, most drug therapy literature rightfully keys in on adverse side effects and the avoidance of mitochondrial toxicity. It is important going forward that we better understand the role and function of mitochondria in both health and the disease states in order to better take advantage of opportunities and potential therapeutic benefits of mitochondrial and metabolic manipulation</p></list-item></list></sec></boxed-text></sec></body><back><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">ATP</term><def><p>adenosine triphosphate</p></def></def-item><def-item><term id="uid2">ETC</term><def><p>electron transport chain</p></def></def-item><def-item><term id="uid3">HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term id="uid4">IFN-I</term><def><p>type I interferons</p></def></def-item><def-item><term id="uid5">MOMP</term><def><p>mitochondrial outer membrane permeabilization</p></def></def-item><def-item><term id="uid6">mtDNA</term><def><p>mitochondrial DNA</p></def></def-item><def-item><term id="uid7">mtROS</term><def><p>mitochondrial ROS</p></def></def-item><def-item><term id="uid8">NRTIs</term><def><p>nucleoside reverse transcriptase inhibitors</p></def></def-item><def-item><term id="uid9">OXPHOS</term><def><p>oxidative phosphorylation</p></def></def-item><def-item><term id="uid10">PD</term><def><p>Parkinson's disease</p></def></def-item><def-item><term id="uid11">PDH</term><def><p>pyruvate dehydrogenase</p></def></def-item><def-item><term id="uid12">PRRs</term><def><p>pattern recognition receptors</p></def></def-item><def-item><term id="uid13">RNA</term><def><p>ribonucleic acid</p></def></def-item><def-item><term id="uid14">ROS</term><def><p>reactive oxygen species</p></def></def-item><def-item><term id="uid15">SNPs</term><def><p>single-nucleotide polymorphisms</p></def></def-item><def-item><term id="uid16">TLR9</term><def><p>Toll-like receptor 9</p></def></def-item><def-item><term id="uid17">TOP1MT</term><def><p>topoisomerase IB</p></def></def-item><def-item><term id="uid18">TRAIL</term><def><p>tumour necrosis-related apoptosis-inducing ligand</p></def></def-item><def-item><term id="uid19">UCP2</term><def><p>uncoupling protein 2.</p></def></def-item></def-list></glossary><sec id="s8" sec-type="author-contrib"><title>Author Contribution</title><p>All authors contributed to, read and approved the final version of the manuscript.</p></sec><sec id="s9" sec-type="funding"><title>Funding</title><p>M.S. was supported by the ME Association</p></sec><sec id="s10" sec-type="COI-statement"><title>Competing Interests</title><p>The Authors declare that there are no competing interests associated with the manuscript.</p></sec><ref-list><title>References</title><ref id="BST-47-1757C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudkina</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kou&#x00159;il</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Braun</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Boekema</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>) <article-title>Structure and function of mitochondrial supercomplexes</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1797</volume>, <fpage>664</fpage>&#x02013;<lpage>670</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbabio.2009.12.013</pub-id><pub-id pub-id-type="pmid">20036212</pub-id></mixed-citation></ref><ref id="BST-47-1757C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taanman</surname><given-names>J.</given-names></name></person-group> (<year>1999</year>) <article-title>The mitochondrial genome: structure, transcription, translation and replication</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1410</volume>, <fpage>103</fpage>&#x02013;<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1016/S0005-2728(98)00161-3</pub-id><pub-id pub-id-type="pmid">10076021</pub-id></mixed-citation></ref><ref id="BST-47-1757C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Erchia</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Atlante</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Gadaleta</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Pavesi</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Chiara</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>De Virgilio</surname><given-names>C.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Tissue-specific mtDNA abundance from exome data and its correlation with mitochondrial transcription, mass and respiratory activity</article-title>. <source>Mitochondrion</source>
<volume>20</volume>, <fpage>13</fpage>&#x02013;<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2014.10.005</pub-id><pub-id pub-id-type="pmid">25446395</pub-id></mixed-citation></ref><ref id="BST-47-1757C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkman</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>ter Hofstede</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Burger</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Smeitink</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Koopmans</surname><given-names>P.</given-names></name></person-group> (<year>1998</year>) <article-title>Adverse effects of reverse transcriptase inhibitors</article-title>. <source>AIDS</source>
<volume>12</volume>, <fpage>1735</fpage>&#x02013;<lpage>1744</lpage>
<pub-id pub-id-type="doi">10.1097/00002030-199814000-00004</pub-id><pub-id pub-id-type="pmid">9792373</pub-id></mixed-citation></ref><ref id="BST-47-1757C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Santoro</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Salvioli</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>) <article-title>Mitochondria and mitochondria-induced signalling molecules as longevity determinants</article-title>. <source>Mech. Ageing Dev.</source>
<volume>165</volume>, <fpage>115</fpage>&#x02013;<lpage>128</lpage>
<pub-id pub-id-type="doi">10.1016/j.mad.2016.12.002</pub-id><pub-id pub-id-type="pmid">27964991</pub-id></mixed-citation></ref><ref id="BST-47-1757C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wai</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Ao</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Cyr</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Dufort</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Shoubridge</surname><given-names>E.</given-names></name></person-group> (<year>2010</year>) <article-title>The role of mitochondrial DNA copy number in mammalian fertility</article-title>. <source>Biol. Reprod.</source>
<volume>83</volume>, <fpage>52</fpage>&#x02013;<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1095/biolreprod.109.080887</pub-id><pub-id pub-id-type="pmid">20130269</pub-id></mixed-citation></ref><ref id="BST-47-1757C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benard</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Faustin</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Passerieux</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Galinier</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Rocher</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Bellance</surname><given-names>N.</given-names></name><etal>et al.</etal></person-group> (<year>2006</year>) <article-title>Physiological diversity of mitochondrial oxidative phosphorylation</article-title>. <source>Am. J. Physiol. Cell Physiol.</source>
<volume>291</volume>, <fpage>1172</fpage>&#x02013;<lpage>1182</lpage>
<pub-id pub-id-type="doi">10.1152/ajpcell.00195.2006</pub-id></mixed-citation></ref><ref id="BST-47-1757C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Samuels</surname><given-names>D.C.</given-names></name>, <name name-style="western"><surname>Wonnapinij</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Chinnery</surname><given-names>P.F.</given-names></name></person-group> (<year>2013</year>) <article-title>Preventing the transmission of pathogenic mitochondrial DNA mutations: can we achieve long-term benefits from germ-line gene transfer?</article-title>
<source>Hum. Reprod.</source>
<volume>28</volume>, <fpage>554</fpage>&#x02013;<lpage>559</lpage>
<pub-id pub-id-type="doi">10.1093/humrep/des439</pub-id><pub-id pub-id-type="pmid">23297368</pub-id></mixed-citation></ref><ref id="BST-47-1757C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Course</surname><given-names>M.W.X.</given-names></name></person-group> (<year>2016</year>) <article-title>Transporting mitochondria in neurons</article-title>. <source>F1000Research</source>
<volume>5</volume>, <fpage>1735</fpage>
<pub-id pub-id-type="doi">10.12688/f1000research.7864.1</pub-id></mixed-citation></ref><ref id="BST-47-1757C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>Z.H.</given-names></name> and <name name-style="western"><surname>Cai</surname><given-names>Q.</given-names></name></person-group> (<year>2012</year>) <article-title>Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration</article-title>. <source>Nat. Rev. Neurosci.</source>
<volume>13</volume>, <fpage>77</fpage>&#x02013;<lpage>93</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3156</pub-id><pub-id pub-id-type="pmid">22218207</pub-id></mixed-citation></ref><ref id="BST-47-1757C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magran&#x000e9;</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Manfredi</surname><given-names>G.</given-names></name></person-group> (<year>2009</year>) <article-title>Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis</article-title>. <source>Antioxid. Redox. Signal.</source>
<volume>11</volume>, <fpage>1615</fpage>&#x02013;<lpage>1626</lpage>
<pub-id pub-id-type="doi">10.1089/ars.2009.2604</pub-id><pub-id pub-id-type="pmid">19344253</pub-id></mixed-citation></ref><ref id="BST-47-1757C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>P.H.</given-names></name> and <name name-style="western"><surname>Shirendeb</surname><given-names>U.P.</given-names></name></person-group> (<year>2012</year>) <article-title>Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1822</volume>, <fpage>101</fpage>&#x02013;<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2011.10.016</pub-id><pub-id pub-id-type="pmid">22080977</pub-id></mixed-citation></ref><ref id="BST-47-1757C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lemasters</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Theruvath</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name> and <name name-style="western"><surname>Nieminen</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>) <article-title>Mitochondrial calcium and the permeability transition in cell death</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1787</volume>, <fpage>1395</fpage>&#x02013;<lpage>1401</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbabio.2009.06.009</pub-id><pub-id pub-id-type="pmid">19576166</pub-id></mixed-citation></ref><ref id="BST-47-1757C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Celsi</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Pizzo</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Brini</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Leo</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fotino</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Pinton</surname><given-names>P.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>) <article-title>Mitochondria, calcium and cell death: a deadly triad in neurodegeneration</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1787</volume>, <fpage>335</fpage>&#x02013;<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbabio.2009.02.021</pub-id><pub-id pub-id-type="pmid">19268425</pub-id></mixed-citation></ref><ref id="BST-47-1757C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stehling</surname><given-names>O.</given-names></name> and <name name-style="western"><surname>Lill</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>) <article-title>The role of mitochondria in cellular iron-sulfur protein biogenesis: mechanisms, connected processes, and diseases</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source>
<volume>5</volume>, <fpage>a011312</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a011312</pub-id><pub-id pub-id-type="pmid">23906713</pub-id></mixed-citation></ref><ref id="BST-47-1757C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A.P.</given-names></name> and <name name-style="western"><surname>Shadel</surname><given-names>G.</given-names></name></person-group> (<year>2017</year>) <article-title>Mitochondrial DNA in innate immune responses and inflammatory pathology</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>17</volume>, <fpage>363</fpage>&#x02013;<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1038/nri.2017.21</pub-id><pub-id pub-id-type="pmid">28393922</pub-id></mixed-citation></ref><ref id="BST-47-1757C17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Youle</surname><given-names>R.</given-names></name></person-group> (<year>2019</year>) <article-title>Mitochondria &#x02014; striking a balance between host and endosymbiont</article-title>. <source>Science</source>
<volume>365</volume>, <fpage>655</fpage>&#x02013;<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1126/science.aaw9855</pub-id></mixed-citation></ref><ref id="BST-47-1757C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapnick</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Pacheco</surname><given-names>S.E.</given-names></name> and <name name-style="western"><surname>McGuire</surname><given-names>P.J.</given-names></name></person-group> (<year>2018</year>) <article-title>The emerging role of immune dysfunction in mitochondrial diseases as a paradigm for understanding immunometabolism</article-title>. <source>Metabolism</source>
<volume>81</volume>, <fpage>97</fpage>&#x02013;<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1016/j.metabol.2017.11.010</pub-id><pub-id pub-id-type="pmid">29162500</pub-id></mixed-citation></ref><ref id="BST-47-1757C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pernas</surname><given-names>L.</given-names></name> and <name name-style="western"><surname>Scorrano</surname><given-names>L.</given-names></name></person-group> (<year>2016</year>) <article-title>Mito-morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function</article-title>. <source>Annu. Rev. Physiol.</source>
<volume>78</volume>, <fpage>505</fpage>&#x02013;<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-physiol-021115-105011</pub-id><pub-id pub-id-type="pmid">26667075</pub-id></mixed-citation></ref><ref id="BST-47-1757C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>J.A.</given-names></name> and <name name-style="western"><surname>Ding</surname><given-names>W.X.</given-names></name></person-group> (<year>2018</year>) <article-title>Mechanisms, pathophysiological roles and methods for analyzing mitophagy &#x02014; recent insights</article-title>. <source>Biol. Chem.</source>
<volume>399</volume>, <fpage>147</fpage>&#x02013;<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1515/hsz-2017-0228</pub-id><pub-id pub-id-type="pmid">28976892</pub-id></mixed-citation></ref><ref id="BST-47-1757C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diot</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Morten</surname><given-names>K.</given-names></name> and <name name-style="western"><surname>Poulton</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>) <article-title>Mitophagy plays a central role in mitochondrial ageing</article-title>. <source>Mamm. Genome</source>
<volume>27</volume>, <fpage>381</fpage>&#x02013;<lpage>395</lpage>
<pub-id pub-id-type="doi">10.1007/s00335-016-9651-x</pub-id><pub-id pub-id-type="pmid">27352213</pub-id></mixed-citation></ref><ref id="BST-47-1757C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lewin</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Ash</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>) <article-title>Mitochondria: potential targets for protection in age-related macular degeneration</article-title>. <source>Adv. Exp. Med. Biol.</source>
<volume>1074</volume>, <fpage>11</fpage>&#x02013;<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-319-75402-4_2</pub-id><pub-id pub-id-type="pmid">29721922</pub-id></mixed-citation></ref><ref id="BST-47-1757C23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Mitophagy, a potential therapeutic target for stroke</article-title>. <source>J. Biomed. Sci.</source>
<volume>25</volume>, article no. 87 <pub-id pub-id-type="doi">10.1186/s12929-018-0487-4</pub-id></mixed-citation></ref><ref id="BST-47-1757C24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dombi</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Mortiboys</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Poulton</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>) <article-title>Modulating mitophagy in mitochondrial disease</article-title>. <source>Curr. Med. Chem.</source>
<volume>25</volume>, <fpage>5597</fpage>&#x02013;<lpage>5612</lpage>
<pub-id pub-id-type="doi">10.2174/0929867324666170616101741</pub-id></mixed-citation></ref><ref id="BST-47-1757C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berdis</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>) <article-title>DNA polymerases as therapeutic targets</article-title>. <source>Biochemistry</source>
<volume>47</volume>, <fpage>8253</fpage>&#x02013;<lpage>8260</lpage>
<pub-id pub-id-type="doi">10.1021/bi801179f</pub-id></mixed-citation></ref><ref id="BST-47-1757C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>) <article-title>Mitochondrial off targets of drug therapy</article-title>. <source>Trends Pharmacol. Sci.</source>
<volume>29</volume>, <fpage>361</fpage>&#x02013;<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1016/j.tips.2008.04.001</pub-id><pub-id pub-id-type="pmid">18501972</pub-id></mixed-citation></ref><ref id="BST-47-1757C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montessori</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Press</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Akagi</surname><given-names>L.</given-names></name> and <name name-style="western"><surname>Montaner</surname><given-names>J.S.G.</given-names></name></person-group> (<year>2004</year>) <article-title>Adverse effects of antiretroviral therapy for HIV infection</article-title>. <source>CMAJ</source>
<volume>170</volume>, <fpage>229</fpage>&#x02013;<lpage>238</lpage><pub-id pub-id-type="pmid">14734438</pub-id></mixed-citation></ref><ref id="BST-47-1757C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hanes</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name></person-group> (<year>2003</year>) <article-title>Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase</article-title>. <source>Biochemistry</source>
<volume>42</volume>, <fpage>14711</fpage>&#x02013;<lpage>14719</lpage>
<pub-id pub-id-type="doi">10.1021/bi035596s</pub-id><pub-id pub-id-type="pmid">14674745</pub-id></mixed-citation></ref><ref id="BST-47-1757C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birkus</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Hitchcock</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Cihlar</surname><given-names>T.</given-names></name></person-group> (<year>2002</year>) <article-title>Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>46</volume>, <fpage>716</fpage>&#x02013;<lpage>723</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.46.3.716-723.2002</pub-id><pub-id pub-id-type="pmid">11850253</pub-id></mixed-citation></ref><ref id="BST-47-1757C30"><label>30</label><mixed-citation publication-type="std"><person-group person-group-type="author"><collab>U.S.F.A.D. Administration</collab></person-group> (<year>2019</year>) <article-title>Antiretroviral drugs used in the treatment of HIV infection</article-title>, <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/patients/hiv-treatment/antiretroviral-drugs-used-treatment-hiv-infection">https://www.fda.gov/patients/hiv-treatment/antiretroviral-drugs-used-treatment-hiv-infection</ext-link>
<comment>[cited 18 June 2019]</comment>.</mixed-citation></ref><ref id="BST-47-1757C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Guan</surname><given-names>M.X.</given-names></name></person-group> (<year>2009</year>) <article-title>Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>53</volume>, <fpage>4612</fpage>&#x02013;<lpage>4618</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.00965-08</pub-id><pub-id pub-id-type="pmid">19687236</pub-id></mixed-citation></ref><ref id="BST-47-1757C32"><label>32</label><mixed-citation publication-type="std"><person-group person-group-type="author"><collab>NIDCD</collab></person-group> (<year>2019</year>) <article-title>Age-related hearing loss</article-title> , <ext-link ext-link-type="uri" xlink:href="https://www.nidcd.nih.gov/health/age-related-hearing-loss">https://www.nidcd.nih.gov/health/age-related-hearing-loss</ext-link>
<comment>[cited 4 July 2019]</comment>.</mixed-citation></ref><ref id="BST-47-1757C33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golomb</surname><given-names>B.A.</given-names></name> and <name name-style="western"><surname>Evans</surname><given-names>M.A.</given-names></name></person-group> (<year>2018</year>) <article-title>Statin adverse effects</article-title>. <source>Am. J. Cardiovasc. Drugs</source>
<volume>8</volume>, <fpage>373</fpage>&#x02013;<lpage>418</lpage>
<pub-id pub-id-type="doi">10.2165/0129784-200808060-00004</pub-id></mixed-citation></ref><ref id="BST-47-1757C34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>du Souich</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Roederer</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Dufour</surname><given-names>R.</given-names></name></person-group> (<year>2019</year>) <article-title>Myotoxicity of statins: mechanism of action</article-title>. <source>Pharmacol. Ther.</source>
<volume>175</volume>, <fpage>1</fpage>&#x02013;<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.02.029</pub-id></mixed-citation></ref><ref id="BST-47-1757C35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>R.</given-names></name> and <name name-style="western"><surname>Wierzbicki</surname><given-names>A.S.</given-names></name></person-group> (<year>2017</year>) <article-title>Statins, muscle disease and mitochondria</article-title>. <source>J. Clin. Med.</source>
<volume>6</volume>, <fpage>75</fpage>
<pub-id pub-id-type="doi">10.3390/jcm6080075</pub-id></mixed-citation></ref><ref id="BST-47-1757C36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicolson</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Conklin</surname><given-names>K.</given-names></name></person-group> (<year>2007</year>) <article-title>Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy</article-title>. <source>Clin. Exp. Metastasis</source>
<volume>25</volume>, <fpage>161</fpage>&#x02013;<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1007/s10585-007-9129-z</pub-id><pub-id pub-id-type="pmid">18058028</pub-id></mixed-citation></ref><ref id="BST-47-1757C37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finkel</surname><given-names>T.</given-names></name></person-group> (<year>2012</year>) <article-title>Signal transduction by mitochondrial oxidants</article-title>. <source>J. Biol. Chem.</source>
<volume>287</volume>, <fpage>4434</fpage>&#x02013;<lpage>4440</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.R111.271999</pub-id><pub-id pub-id-type="pmid">21832045</pub-id></mixed-citation></ref><ref id="BST-47-1757C38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Mehdi</surname><given-names>A.B.</given-names></name>, <name name-style="western"><surname>Pastukh</surname><given-names>V.M.</given-names></name>, <name name-style="western"><surname>Swiger</surname><given-names>B.M.</given-names></name>, <name name-style="western"><surname>Reed</surname><given-names>D.J.</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name>, <name name-style="western"><surname>Bardwell</surname><given-names>G.C.</given-names></name><etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription</article-title>. <source>Sci. Signal.</source>
<volume>5</volume>, <fpage>ra47</fpage> PMID:<?supplied-pmid 22763339?><pub-id pub-id-type="pmid">22763339</pub-id></mixed-citation></ref><ref id="BST-47-1757C39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ristow</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Zarse</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>) <article-title>How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis)</article-title>. <source>Exp. Gerontol.</source>
<volume>45</volume>, <fpage>410</fpage>&#x02013;<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2010.03.014</pub-id><pub-id pub-id-type="pmid">20350594</pub-id></mixed-citation></ref><ref id="BST-47-1757C40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>T.J.</given-names></name>, <name name-style="western"><surname>Zarse</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Voigt</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Urban</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Birringer</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Ristow</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>) <article-title>Glucose restriction extends <italic>Caenorhabditis elegans</italic> life span by inducing mitochondrial respiration and increasing oxidative stress</article-title>. <source>Cell Metab.</source>
<volume>6</volume>, <fpage>280</fpage>&#x02013;<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2007.08.011</pub-id><pub-id pub-id-type="pmid">17908557</pub-id></mixed-citation></ref><ref id="BST-47-1757C41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diano</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Horvath</surname><given-names>T.L.</given-names></name></person-group> (<year>2012</year>) <article-title>Mitochondrial uncoupling protein 2 (UCP2) in glucose and lipid metabolism</article-title>. <source>Trends Mol. Med.</source>
<volume>18</volume>, <fpage>52</fpage>&#x02013;<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2011.08.003</pub-id><pub-id pub-id-type="pmid">21917523</pub-id></mixed-citation></ref><ref id="BST-47-1757C42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pecqueur</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Alves-Guerra</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Ricquier</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Bouillaud</surname><given-names>F.</given-names></name></person-group> (<year>2009</year>) <article-title>UCP2, a metabolic sensor coupling glucose oxidation to mitochondrial metabolism?</article-title>
<source>IUBMB Life</source>
<volume>61</volume>, <fpage>762</fpage>&#x02013;<lpage>767</lpage>
<pub-id pub-id-type="doi">10.1002/iub.188</pub-id><pub-id pub-id-type="pmid">19514063</pub-id></mixed-citation></ref><ref id="BST-47-1757C43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vozza</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Parisi</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>De Leonardis</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Lasorsa</surname><given-names>F.M.</given-names></name>, <name name-style="western"><surname>Castegna</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Amorese</surname><given-names>D.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation</article-title>. <source>Proc. Natl Acad. Sci. U.S.A.</source>
<volume>111</volume>, <fpage>960</fpage>&#x02013;<lpage>965</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1317400111</pub-id><pub-id pub-id-type="pmid">24395786</pub-id></mixed-citation></ref><ref id="BST-47-1757C44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Chisholm</surname><given-names>A.D.</given-names></name></person-group> (<year>2014</year>) <article-title><italic>C. elegans</italic> epidermal wounding induces a mitochondrial ROS burst that promotes wound repair</article-title>. <source>Dev. Cell</source>
<volume>31</volume>, <fpage>48</fpage>&#x02013;<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2014.08.002</pub-id><pub-id pub-id-type="pmid">25313960</pub-id></mixed-citation></ref><ref id="BST-47-1757C45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schieber</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Chandel</surname><given-names>N.S.</given-names></name></person-group> (<year>2014</year>) <article-title>TOR signaling couples oxygen sensing to lifespan in <italic>C. elegans</italic></article-title>. <source>Cell Rep.</source>
<volume>9</volume>, <fpage>9</fpage>&#x02013;<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2014.08.075</pub-id><pub-id pub-id-type="pmid">25284791</pub-id></mixed-citation></ref><ref id="BST-47-1757C46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Allman</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Nehrke</surname><given-names>K.</given-names></name></person-group> (<year>2012</year>) <article-title>Regulation of acid-base transporters by reactive oxygen species following mitochondrial fragmentation</article-title>. <source>Am. J. Physiol. Cell Physiol.</source>
<volume>302</volume>, <fpage>C1045</fpage>&#x02013;<lpage>C1054</lpage>
<pub-id pub-id-type="doi">10.1152/ajpcell.00411.2011</pub-id><pub-id pub-id-type="pmid">22237403</pub-id></mixed-citation></ref><ref id="BST-47-1757C47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A.P.</given-names></name>, <name name-style="western"><surname>Shadel</surname><given-names>G.S.</given-names></name> and <name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>) <article-title>Mitochondria in innate immune responses</article-title>. <source>Nat. Rev. Immunol.</source>
<volume>11</volume>, <fpage>389</fpage>&#x02013;<lpage>402</lpage>
<pub-id pub-id-type="doi">10.1038/nri2975</pub-id><pub-id pub-id-type="pmid">21597473</pub-id></mixed-citation></ref><ref id="BST-47-1757C48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamanaka</surname><given-names>R.B.</given-names></name>, <name name-style="western"><surname>Glasauer</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hoover</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Blatt</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Mullen</surname><given-names>A.R.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Mitochondrial reactive oxygen species promote epidermal differentiation and hair follicle development</article-title>. <source>Sci. Signal.</source>
<volume>6</volume>, <fpage>ra8</fpage>
<pub-id pub-id-type="doi">10.1126/scisignal.2003638</pub-id><pub-id pub-id-type="pmid">23386745</pub-id></mixed-citation></ref><ref id="BST-47-1757C49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contreras-Shannon</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Heart</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Paredes</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Navaira</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Catano</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Maffi</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells</article-title>. <source>PLoS ONE</source>
<volume>8</volume>, <fpage>e59012</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0059012</pub-id><pub-id pub-id-type="pmid">23527073</pub-id></mixed-citation></ref><ref id="BST-47-1757C50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baig</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Navaira</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Escamilla</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Raventos</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Walss-Bass</surname><given-names>C.</given-names></name></person-group> (<year>2010</year>) <article-title>Clozapine treatment causes oxidation of proteins involved in energy metabolism in lymphoblastoid cells: a possible mechanism for antipsychotic-induced metabolic alterations</article-title>. <source>J. Psychiatr. Pract.</source>
<volume>16</volume>, <fpage>325</fpage>&#x02013;<lpage>333</lpage>
<pub-id pub-id-type="doi">10.1097/01.pra.0000388627.36781.6a</pub-id><pub-id pub-id-type="pmid">20859109</pub-id></mixed-citation></ref><ref id="BST-47-1757C51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komulainen</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Lodge</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hinttala</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Bolszak</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pietil&#x000e4;</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Koivunen</surname><given-names>P.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model</article-title>. <source>Toxicol. Appl. Pharmacol.</source>
<volume>331</volume>, <fpage>47</fpage>&#x02013;<lpage>56</lpage> PMID:<?supplied-pmid 25745980?><pub-id pub-id-type="pmid">25745980</pub-id></mixed-citation></ref><ref id="BST-47-1757C52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ruiter</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>IJlst</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Jakobs</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Duran</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>de Almeida</surname><given-names>I.</given-names></name><etal>et al.</etal></person-group> (<year>1997</year>) <article-title>Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro</article-title>. <source>J. Inherit. Metab. Dis.</source>
<volume>20</volume>, <fpage>397</fpage>&#x02013;<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1023/A:1005398516208</pub-id><pub-id pub-id-type="pmid">9266365</pub-id></mixed-citation></ref><ref id="BST-47-1757C53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zaheeruddin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Shenoy</surname><given-names>N.</given-names></name> and <name name-style="western"><surname>Vani</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>) <article-title>Fetal valproate syndrome</article-title>. <source>Indian J. Pediatr.</source>
<volume>73</volume></mixed-citation></ref><ref id="BST-47-1757C54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Will</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Dykens</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>) <article-title>Mitochondrial toxicity assessment in industry &#x02014; a decade of technology development and insight</article-title>. <source>Expert. Opin. Drug. Metab. Toxicol.</source>
<volume>10</volume>, <fpage>1061</fpage>&#x02013;<lpage>1067</lpage>
<pub-id pub-id-type="doi">10.1517/17425255.2014.939628</pub-id><pub-id pub-id-type="pmid">25023361</pub-id></mixed-citation></ref><ref id="BST-47-1757C55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matthews</surname><given-names>T.</given-names></name> and <name name-style="western"><surname>Boehme</surname><given-names>R.</given-names></name></person-group> (<year>1988</year>) <article-title>Antiviral activity and mechanism of action of ganciclovir</article-title>. <source>Clin. Infect. Dis.</source>
<volume>10</volume>, <fpage>490</fpage>&#x02013;<lpage>494</lpage>
<pub-id pub-id-type="doi">10.1093/clinids/10.Supplement_3.S490</pub-id></mixed-citation></ref><ref id="BST-47-1757C56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Margolis</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Heverling</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Pham</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Stolbach</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>) <article-title>A review of the toxicity of HIV medications</article-title>. <source>J. Med. Toxicol.</source>
<volume>10</volume>, <fpage>26</fpage>&#x02013;<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1007/s13181-013-0325-8</pub-id></mixed-citation></ref><ref id="BST-47-1757C57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name> and <name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>) <article-title>Mitochondrial DNA in the regulation of innate immune responses</article-title>. <source>Protein Cell</source>
<volume>7</volume>, <fpage>11</fpage>&#x02013;<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1007/s13238-015-0222-9</pub-id></mixed-citation></ref><ref id="BST-47-1757C58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>) <article-title>The mitochondrial basis of aging and age-related disorders</article-title>. <source>Genes</source>
<volume>8</volume>, <fpage>398</fpage>
<pub-id pub-id-type="doi">10.3390/genes8120398</pub-id></mixed-citation></ref><ref id="BST-47-1757C59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><etal>et al.</etal></person-group> (<year>2005</year>) <article-title>Increased oxidative damage with altered antioxidative status in type 2 diabetic patients harboring the 16189T to C variant of mitochondrial DNA</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>1042</volume>, <fpage>64</fpage>&#x02013;<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1338.007</pub-id><pub-id pub-id-type="pmid">15965046</pub-id></mixed-citation></ref><ref id="BST-47-1757C60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinti</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fink</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Hathaway</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Durr</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kunovac</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Hollander</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>) <article-title>Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis</article-title>. <source>Am. J. Physiol.-Endocrinol. Metab.</source>
<volume>316</volume>, <fpage>E268</fpage>&#x02013;<lpage>E285</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00314.2018</pub-id><pub-id pub-id-type="pmid">30601700</pub-id></mixed-citation></ref><ref id="BST-47-1757C61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>) <article-title>Role of mitochondrial DNA variation in the pathogenesis of diabetes mellitus</article-title>. <source>Front. Biosci.</source>
<volume>21</volume>, <fpage>1151</fpage>&#x02013;<lpage>1167</lpage>
<pub-id pub-id-type="doi">10.2741/4447</pub-id></mixed-citation></ref><ref id="BST-47-1757C62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheu-Grau</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gomez-Duran</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Iglesias</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Lopez-Gallardo</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Montoya</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Ruiz-Pesini</surname><given-names>E.</given-names></name></person-group> (<year>2012</year>) <article-title>Mitochondrial antibiograms in personalized medicine</article-title>. <source>Hum. Mol. Genet.</source>
<volume>22</volume>, <fpage>1132</fpage>&#x02013;<lpage>1139</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds517</pub-id><pub-id pub-id-type="pmid">23223015</pub-id></mixed-citation></ref><ref id="BST-47-1757C63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Will</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Nadanaciva</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>) <article-title>Mitochondrial bioenergetics and drug-induced toxicity in a panel of mouse embryonic fibroblasts with mitochondrial DNA single nucleotide polymorphisms</article-title>. <source>Toxicol. Appl. Pharmacol.</source>
<volume>264</volume>, <fpage>167</fpage>&#x02013;<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/j.taap.2012.07.030</pub-id><pub-id pub-id-type="pmid">22889881</pub-id></mixed-citation></ref><ref id="BST-47-1757C64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canter</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Haas</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Kallianpur</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ritchie</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Robbins</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Shafer</surname><given-names>R.</given-names></name><etal>et al.</etal></person-group> (<year>2007</year>) <article-title>The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy</article-title>. <source>Pharmacogenomics J.</source>
<volume>8</volume>, <fpage>71</fpage>&#x02013;<lpage>77</lpage>
<pub-id pub-id-type="doi">10.1038/sj.tpj.6500470</pub-id><pub-id pub-id-type="pmid">17684475</pub-id></mixed-citation></ref><ref id="BST-47-1757C65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampira</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Kumwenda</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>van Oosterhout</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Dandara</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>) <article-title>Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in Malawian adults on stavudine containing highly active antiretroviral therapy</article-title>. <source>J. Acquir. Immune Defic. Syndr.</source>
<volume>63</volume>, <fpage>647</fpage>&#x02013;<lpage>652</lpage>
<pub-id pub-id-type="doi">10.1097/QAI.0b013e3182968ea5</pub-id><pub-id pub-id-type="pmid">23614993</pub-id></mixed-citation></ref><ref id="BST-47-1757C66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrabou</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Soriano</surname><given-names>&#x000c0;.</given-names></name>, <name name-style="western"><surname>Pin&#x000f3;s</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Casanova-Moll&#x000e0;</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Pacheu-Grau</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Mor&#x000e9;n</surname><given-names>C.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>61</volume>, <fpage>e00542</fpage>&#x02013;<lpage>e00517</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.00542-17</pub-id><pub-id pub-id-type="pmid">28674062</pub-id></mixed-citation></ref><ref id="BST-47-1757C67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahler</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Cass</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Braas</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>York</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bensinger</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Doxycycline alters metabolism and proliferation of human cell lines</article-title>. <source>PLoS ONE</source>
<volume>8</volume>, <fpage>e64561</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0064561</pub-id><pub-id pub-id-type="pmid">23741339</pub-id></mixed-citation></ref><ref id="BST-47-1757C68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son K</surname><given-names>F.S.</given-names></name>, <name name-style="western"><surname>Iida</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Furukawa</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Fujita</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Yamada</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Chiao</surname><given-names>P.J.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>) <article-title>Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells</article-title>. <source>Anticancer Res.</source>
<volume>29</volume>, <fpage>3995</fpage>&#x02013;<lpage>4003</lpage><pub-id pub-id-type="pmid">19846942</pub-id></mixed-citation></ref><ref id="BST-47-1757C69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potter</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Newport</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Morten</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>) <article-title>The Warburg effect: 80 years on</article-title>. <source>Biochem. Soc. Trans.</source>
<volume>44</volume>, <fpage>1499</fpage>&#x02013;<lpage>1505</lpage>
<pub-id pub-id-type="doi">10.1042/BST20160094</pub-id><pub-id pub-id-type="pmid">27911732</pub-id></mixed-citation></ref><ref id="BST-47-1757C70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirpara</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Eu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Clement</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance</article-title>. <source>Redox Biol.</source>
<volume>101076</volume> PMID:<?supplied-pmid 30642723?><pub-id pub-id-type="pmid">30642723</pub-id></mixed-citation></ref><ref id="BST-47-1757C71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>A.S.</given-names></name>, <name name-style="western"><surname>Baty</surname><given-names>J.W.</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>L.F.</given-names></name>, <name name-style="western"><surname>Bezawork-Geleta</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Endaya</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Goodwin</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA</article-title>. <source>Cell Metab.</source>
<volume>6</volume>, <fpage>81</fpage>&#x02013;<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.003</pub-id></mixed-citation></ref><ref id="BST-47-1757C72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelley</surname><given-names>L.C.</given-names></name>, <name name-style="western"><surname>Chi</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>C&#x000e1;ceres</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Hastie</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Schindler</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Adaptive F-actin polymerization and localized ATP production drive basement membrane invasion in the absence of MMPs</article-title>. <source>Dev. Cell</source>
<volume>48</volume>, <fpage>313</fpage>&#x02013;<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2018.12.018</pub-id><pub-id pub-id-type="pmid">30686527</pub-id></mixed-citation></ref><ref id="BST-47-1757C73"><label>73</label><mixed-citation publication-type="std"><person-group person-group-type="author"><collab>Oncoceutics</collab></person-group>
<article-title>ONC201 clinical trials 2019</article-title>, <ext-link ext-link-type="uri" xlink:href="https://oncoceutics.com">https://oncoceutics.com</ext-link>
<comment>[cited 9 July 2019]</comment></mixed-citation></ref><ref id="BST-47-1757C74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Krigsfeld</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Mayes</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Dicker</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects</article-title>. <source>Sci. Transl. Med.</source>
<volume>5</volume>, <fpage>171ra17</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3004828</pub-id></mixed-citation></ref><ref id="BST-47-1757C75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greer</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Porat-Shliom</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Nagashima</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Stuelten</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Crooks</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Koparde</surname><given-names>V.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>ONC201 kills breast cancer cells in vitro by targeting mitochondria</article-title>. <source>Oncotarget</source>
<volume>9</volume>
<pub-id pub-id-type="doi">10.18632/oncotarget.24862</pub-id></mixed-citation></ref><ref id="BST-47-1757C76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graves</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Aponte-Collazo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Fennell</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Graves</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Hale</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Dicheva</surname><given-names>N.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues</article-title>. <source>ACS Chem. Biol.</source>
<volume>14</volume>, <fpage>1020</fpage>&#x02013;<lpage>1029</lpage>
<pub-id pub-id-type="doi">10.1021/acschembio.9b00222</pub-id><pub-id pub-id-type="pmid">31021596</pub-id></mixed-citation></ref><ref id="BST-47-1757C77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishizawa</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Zarabi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Halgas</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Nii</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Jitkova</surname><given-names>Y.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality</article-title>. <source>Cancer Cell</source>
<volume>35</volume>, <fpage>721</fpage>&#x02013;<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1016/j.ccell.2019.03.014</pub-id><pub-id pub-id-type="pmid">31056398</pub-id></mixed-citation></ref><ref id="BST-47-1757C78"><label>78</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Castro e Santos</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Cust&#x000f3;dio</surname><given-names>J.</given-names></name></person-group>, (<year>2015</year>) <chapter-title>Mitochondrial dysfunction on the toxic effects of anticancer agents &#x02014; from lab bench to bedside</chapter-title> In <source>Toxicology Studies &#x02014; Cells, Drugs and Environment</source> (Andreazza, A.C. and Scola, G. eds), pp. <fpage>23</fpage>-<lpage>59</lpage>, <comment>IntechOpen</comment></mixed-citation></ref><ref id="BST-47-1757C79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Ketogenic diet for treatment of intractable epilepsy in adults: a meta-analysis of observational studies</article-title>. <source>Epilepsia Open</source>
<volume>3</volume>, <fpage>9</fpage>&#x02013;<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1002/epi4.12098</pub-id></mixed-citation></ref><ref id="BST-47-1757C80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sofou</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Dahlin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hallb&#x000f6;&#x000f6;k</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Lindefeldt</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Viggedal</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Darin</surname><given-names>N.</given-names></name></person-group> (<year>2017</year>) <article-title>Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes</article-title>. <source>J. Inherit. Metab. Dis.</source>
<volume>40</volume>, <fpage>237</fpage>&#x02013;<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-016-0011-5</pub-id><pub-id pub-id-type="pmid">28101805</pub-id></mixed-citation></ref><ref id="BST-47-1757C81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunn</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Guy</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Bell</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>) <article-title>The quantum mitochondrion and optimal health</article-title>. <source>Biochem. Soc. Trans.</source>
<volume>44</volume>, <fpage>1101</fpage>&#x02013;<lpage>1110</lpage>
<pub-id pub-id-type="doi">10.1042/BST20160096</pub-id><pub-id pub-id-type="pmid">27528758</pub-id></mixed-citation></ref><ref id="BST-47-1757C82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Artero</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Artero</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Tar&#x000ed;n</surname><given-names>J.J.</given-names></name> and <name name-style="western"><surname>Cano</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>) <article-title>The impact of moderate wine consumption on health</article-title>. <source>Maturitas</source>
<volume>80</volume>, <fpage>3</fpage>&#x02013;<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1016/j.maturitas.2014.09.007</pub-id><pub-id pub-id-type="pmid">25449821</pub-id></mixed-citation></ref><ref id="BST-47-1757C83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gohil</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Offner</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sheth</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Fossale</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Gusella</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Meclizine is neuroprotective in models of Huntington's disease</article-title>. <source>Hum. Mol. Genet.</source>
<volume>20</volume>, <fpage>294</fpage>&#x02013;<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddq464</pub-id><pub-id pub-id-type="pmid">20977989</pub-id></mixed-citation></ref><ref id="BST-47-1757C84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gohil</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Cracan</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Yaseen</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Jain</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Meclizine inhibits mitochondrial respiration through direct targeting of cytosolic phosphoethanolamine metabolism</article-title>. <source>J. Biol. Chem.</source>
<volume>288</volume>, <fpage>35387</fpage>&#x02013;<lpage>35395</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.489237</pub-id><pub-id pub-id-type="pmid">24142790</pub-id></mixed-citation></ref><ref id="BST-47-1757C85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chau</surname><given-names>K.</given-names></name> and <name name-style="western"><surname>Schapira</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>) <article-title>Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models</article-title>. <source>Sci. Rep.</source>
<volume>6</volume>, <fpage>25344</fpage> PMID:<?supplied-pmid 27145922?><pub-id pub-id-type="pmid">27145922</pub-id></mixed-citation></ref><ref id="BST-47-1757C86"><label>86</label><mixed-citation publication-type="journal"><comment>Cancer Research UK.</comment> (<year>2019</year>) <comment>Worldwide cancer statistics</comment>, <ext-link ext-link-type="uri" xlink:href="https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer">https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer</ext-link>
<comment>[cited 13 March 2019]</comment>.</mixed-citation></ref><ref id="BST-47-1757C87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warburg</surname><given-names>O.</given-names></name></person-group> (<year>1927</year>) <article-title>The metabolism of tumors in the body</article-title>. <source>J. Gen. Physiol.</source>
<volume>8</volume>, <fpage>519</fpage>&#x02013;<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1085/jgp.8.6.519</pub-id><pub-id pub-id-type="pmid">19872213</pub-id></mixed-citation></ref><ref id="BST-47-1757C88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malviya</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Nayak</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>) <article-title>PET imaging to monitor cancer therapy</article-title>. <source>Curr. Pharm. Biotechnol.</source>
<volume>14</volume>, <fpage>669</fpage>&#x02013;<lpage>682</lpage>
<pub-id pub-id-type="doi">10.2174/1389201014666131226104750</pub-id></mixed-citation></ref><ref id="BST-47-1757C89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pustylnikov</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Costabile</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Beghi</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Facciabene</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>) <article-title>Targeting mitochondria in cancer: current concepts and immunotherapy approaches</article-title>. <source>Transl. Res.</source>
<volume>202</volume>, <fpage>35</fpage>&#x02013;<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1016/j.trsl.2018.07.013</pub-id><pub-id pub-id-type="pmid">30144423</pub-id></mixed-citation></ref><ref id="BST-47-1757C90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>) <article-title>Mitochondria and cancer</article-title>. <source>Nat. Rev. Cancer</source>
<volume>12</volume>, <fpage>685</fpage>&#x02013;<lpage>698</lpage>
<pub-id pub-id-type="doi">10.1038/nrc3365</pub-id><pub-id pub-id-type="pmid">23001348</pub-id></mixed-citation></ref><ref id="BST-47-1757C91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Alexandrov</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Gerstung</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Martincorena</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Nik-Zainal</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ramakrishna</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2014</year>) <article-title>Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer</article-title>. <source>eLife</source>
<volume>3</volume>, <fpage>e02935</fpage> PMID:<?supplied-pmid 25271376?><pub-id pub-id-type="pmid">25271376</pub-id></mixed-citation></ref><ref id="BST-47-1757C92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Iyer</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma</article-title>. <source>Nature</source>
<volume>567</volume>, <fpage>341</fpage>&#x02013;<lpage>346</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-019-0993-x</pub-id><pub-id pub-id-type="pmid">30842654</pub-id></mixed-citation></ref><ref id="BST-47-1757C93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molina</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Protopopova</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Gera</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Bandi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bristow</surname><given-names>C.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>An inhibitor of oxidative phosphorylation exploits cancer vulnerability</article-title>. <source>Nat. Med.</source>
<volume>24</volume>, <fpage>1036</fpage>&#x02013;<lpage>1046</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-018-0052-4</pub-id><pub-id pub-id-type="pmid">29892070</pub-id></mixed-citation></ref><ref id="BST-47-1757C94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma</article-title>. <source>Sci. Transl. Med.</source>
<volume>11</volume>, <fpage>eaau1167</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aau1167</pub-id><pub-id pub-id-type="pmid">31068440</pub-id></mixed-citation></ref><ref id="BST-47-1757C95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu Y</surname><given-names>Z.X.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nan</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name> and <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group> (<year>2017</year>) <article-title>Mitochondrial-targeting lonidamine-doxorubicin nanoparticles for synergistic chemotherapy to conquer drug resistance</article-title>. <source>ACS Appl. Mater Interfaces</source>
<volume>9</volume>, <fpage>43498</fpage>&#x02013;<lpage>43507</lpage>
<pub-id pub-id-type="doi">10.1021/acsami.7b14577</pub-id><pub-id pub-id-type="pmid">29171954</pub-id></mixed-citation></ref><ref id="BST-47-1757C96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozanov</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Cheltsov</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Nilsen</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Boniface</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Forquer</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Korkola</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity</article-title>. <source>PLoS ONE</source>
<volume>14</volume>, <fpage>e0205623</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0205623</pub-id><pub-id pub-id-type="pmid">30908483</pub-id></mixed-citation></ref><ref id="BST-47-1757C97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashton</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Fokas</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Kunz-Schughart</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Folkes</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Anbalagan</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Huether</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia</article-title>. <source>Nat. Commun.</source>
<volume>7</volume>
<pub-id pub-id-type="doi">10.1038/ncomms12308</pub-id></mixed-citation></ref><ref id="BST-47-1757C98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrzejewski</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Siegel</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>St-Pierre</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>) <article-title>Metabolic profiles associated with metformin efficacy in cancer</article-title>. <source>Front. Endocrinol.</source>
<volume>9</volume>, <fpage>372</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2018.00372</pub-id></mixed-citation></ref><ref id="BST-47-1757C99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hirpara</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Eu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Sethi</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Goh</surname><given-names>B.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors</article-title>. <source>Redox Biol.</source>
<volume>101073</volume>
<pub-id pub-id-type="doi">10.1016/j.redox.2018.101073</pub-id></mixed-citation></ref><ref id="BST-47-1757C100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porporato</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Filigheddu</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Pedro</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group> (<year>2017</year>) <article-title>Mitochondrial metabolism and cancer</article-title>. <source>Cell Res.</source>
<volume>28</volume>, <fpage>265</fpage>&#x02013;<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1038/cr.2017.155</pub-id><pub-id pub-id-type="pmid">29219147</pub-id></mixed-citation></ref><ref id="BST-47-1757C101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavez</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Miranda</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Pichiule</surname><given-names>P.</given-names></name> and <name name-style="western"><surname>Chavez</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>) <article-title>Mitochondria and hypoxia-induced gene expression mediated by hypoxia-inducible factors</article-title>. <source>Ann. N. Y. Acad. Sci.</source>
<volume>1147</volume>, <fpage>312</fpage>&#x02013;<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1196/annals.1427.021</pub-id><pub-id pub-id-type="pmid">19076453</pub-id></mixed-citation></ref><ref id="BST-47-1757C102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calabrese</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Iommarini</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Kurelac</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Calvaruso</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Capristo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lollini</surname><given-names>P.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells</article-title>. <source>Cancer Metab.</source>
<volume>1</volume>, <fpage>11</fpage>
<pub-id pub-id-type="doi">10.1186/2049-3002-1-11</pub-id><pub-id pub-id-type="pmid">24280190</pub-id></mixed-citation></ref><ref id="BST-47-1757C103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonner</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Karlsson</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Rodolfo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Arnold</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Vergani</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Arbiser</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>) <article-title>Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo</article-title>. <source>Oncotarget</source>
<volume>7</volume>
<pub-id pub-id-type="doi">10.18632/oncotarget.7289</pub-id></mixed-citation></ref><ref id="BST-47-1757C104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altieri</surname><given-names>D.C.</given-names></name></person-group> (<year>2019</year>) <article-title>Mitochondrial dynamics and metastasis</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>76</volume>, <fpage>827</fpage>&#x02013;<lpage>835</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-018-2961-2</pub-id><pub-id pub-id-type="pmid">30415375</pub-id></mixed-citation></ref><ref id="BST-47-1757C105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>B.J.</given-names></name>, <name name-style="western"><surname>Ho Seo</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Bertolini</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>Myc regulation of a mitochondrial traf&#x0fb01;cking network mediates tumor cell invasion and metastasis</article-title>. <source>Mol. Cell. Biol.</source>
<volume>39</volume>, <fpage>e00109</fpage>&#x02013;<lpage>e00119</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.00109-19</pub-id><pub-id pub-id-type="pmid">31061095</pub-id></mixed-citation></ref><ref id="BST-47-1757C106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>Z.</given-names></name></person-group> (<year>2014</year>) <article-title>Mitochondrial trafficking and anchoring in neurons: new insight and implications</article-title>. <source>J. Cell Biol.</source>
<volume>204</volume>, <fpage>1087</fpage>&#x02013;<lpage>1098</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201312123</pub-id><pub-id pub-id-type="pmid">24687278</pub-id></mixed-citation></ref><ref id="BST-47-1757C107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caino</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Aguinaldo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Wait</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Bryant</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kossenkov</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>A neuronal network of mitochondrial dynamics regulates metastasis</article-title>. <source>Nat. Commun.</source>
<volume>7</volume>, <fpage>13730</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms13730</pub-id><pub-id pub-id-type="pmid">27991488</pub-id></mixed-citation></ref><ref id="BST-47-1757C108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caino</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Rivadeneira</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gabrilovich</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Syntaphilin controls a mitochondrial rheostat for proliferation-motility decisions in cancer</article-title>. <source>J. Clin. Invest.</source>
<volume>127</volume>, <fpage>3755</fpage>&#x02013;<lpage>3769</lpage>
<pub-id pub-id-type="doi">10.1172/JCI93172</pub-id><pub-id pub-id-type="pmid">28891816</pub-id></mixed-citation></ref><ref id="BST-47-1757C109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schieber</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Chandel</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>) <article-title>ROS function in redox signaling and oxidative stress</article-title>. <source>Curr. Biol.</source>
<volume>24</volume>, <fpage>R453</fpage>&#x02013;<lpage>R462</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2014.03.034</pub-id><pub-id pub-id-type="pmid">24845678</pub-id></mixed-citation></ref><ref id="BST-47-1757C110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozanov</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Cheltsov</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sergienko</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Vasile</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Golubkov</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Aleshin</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>TRAIL-based high throughput screening reveals a link between TRAIL-mediated apoptosis and glutathione reductase, a key component of oxidative stress response</article-title>. <source>PLoS ONE</source>
<volume>10</volume>, <fpage>e0129566</fpage> PMID:<?supplied-pmid 26075913?><pub-id pub-id-type="pmid">26075913</pub-id></mixed-citation></ref><ref id="BST-47-1757C111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>) <article-title>Targeting cancer cell mitochondria as a therapeutic approach</article-title>. <source>Future Med. Chem.</source>
<volume>5</volume>, <fpage>53</fpage>&#x02013;<lpage>67</lpage>
<pub-id pub-id-type="doi">10.4155/fmc.12.190</pub-id><pub-id pub-id-type="pmid">23256813</pub-id></mixed-citation></ref><ref id="BST-47-1757C112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilliam</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Fisher-Wellman</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Maples</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cathey</surname><given-names>B.</given-names></name> and <name name-style="western"><surname>Neufer</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>) <article-title>The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle</article-title>. <source>Free Radic. Biol. Med.</source>
<volume>65</volume>, <fpage>988</fpage>&#x02013;<lpage>996</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.08.191</pub-id><pub-id pub-id-type="pmid">24017970</pub-id></mixed-citation></ref><ref id="BST-47-1757C113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shieh</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hung</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name></person-group> (<year>2010</year>) <article-title>Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells</article-title>. <source>Br. J. Pharmacol.</source>
<volume>160</volume>, <fpage>1171</fpage>&#x02013;<lpage>1184</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00746.x</pub-id><pub-id pub-id-type="pmid">20590610</pub-id></mixed-citation></ref><ref id="BST-47-1757C114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammad</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Barbash</surname><given-names>O.</given-names></name> and <name name-style="western"><surname>Creasy</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>) <article-title>Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer</article-title>. <source>Nat. Med.</source>
<volume>25</volume>, <fpage>403</fpage>&#x02013;<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1038/s41591-019-0376-8</pub-id><pub-id pub-id-type="pmid">30842676</pub-id></mixed-citation></ref><ref id="BST-47-1757C115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baechler</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Factor</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Dalla Rosa</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Ravji</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Khiati</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2019</year>) <article-title>The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis</article-title>. <source>Nat. Commun.</source>
<volume>10</volume>
<pub-id pub-id-type="doi">10.1038/s41467-018-07922-3</pub-id></mixed-citation></ref><ref id="BST-47-1757C116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tait</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Green</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>) <article-title>Mitochondria and cell signalling</article-title>. <source>J. Cell Sci.</source>
<volume>125</volume>, <fpage>807</fpage>&#x02013;<lpage>815</lpage>
<pub-id pub-id-type="doi">10.1242/jcs.099234</pub-id><pub-id pub-id-type="pmid">22448037</pub-id></mixed-citation></ref><ref id="BST-47-1757C117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhir</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Dhir</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Borowski</surname><given-names>L.S.</given-names></name>, <name name-style="western"><surname>Jimenez</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Teitell</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>R&#x000f6;tig</surname><given-names>A.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Mitochondrial double-stranded RNA triggers antiviral signalling in humans</article-title>. <source>Nature</source>
<volume>560</volume>, <fpage>238</fpage>&#x02013;<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-018-0363-0</pub-id><pub-id pub-id-type="pmid">30046113</pub-id></mixed-citation></ref><ref id="BST-47-1757C118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohanty</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Tiwari-Pandey</surname><given-names>R.</given-names></name> and <name name-style="western"><surname>Pandey</surname><given-names>N.</given-names></name></person-group> (<year>2019</year>) <article-title>Mitochondria: the indispensable players in innate immunity and guardians of the inflammatory response</article-title>. <source>J. Cell Commun. Signal.</source>
<volume>13</volume>, <fpage>303</fpage>&#x02013;<lpage>318</lpage> PMID:<?supplied-pmid 30719617?><pub-id pub-id-type="pmid">30719617</pub-id></mixed-citation></ref><ref id="BST-47-1757C119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Syed</surname><given-names>G.H.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Siddiqui</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>) <article-title>Mitochondrial dynamics and viral infections: a close nexus</article-title>. <source>Biochim. Biophys. Acta</source>
<volume>1853</volume>, <fpage>2822</fpage>&#x02013;<lpage>2833</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.12.040</pub-id><pub-id pub-id-type="pmid">25595529</pub-id></mixed-citation></ref><ref id="BST-47-1757C120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>C&#x000f4;t&#x000e9;</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Brumme</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Craib</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Wynhoven</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ting</surname><given-names>L.</given-names></name><etal>et al.</etal></person-group> (<year>2002</year>) <article-title>Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients</article-title>. <source>N. Engl. J. Med.</source>
<volume>346</volume>, <fpage>811</fpage>&#x02013;<lpage>820</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa012035</pub-id><pub-id pub-id-type="pmid">11893792</pub-id></mixed-citation></ref><ref id="BST-47-1757C121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Khoury-Hanold</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Staron</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Tal</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pineda</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>Mitochondrial DNA stress primes the antiviral innate immune response</article-title>. <source>Nature</source>
<volume>520</volume>, <fpage>553</fpage>&#x02013;<lpage>557</lpage><pub-id pub-id-type="pmid">25642965</pub-id></mixed-citation></ref><ref id="BST-47-1757C122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Volpi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sims</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Walter</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Traggiai</surname><given-names>E.</given-names></name></person-group> (<year>2019</year>) <article-title>Powering the immune system: mitochondria in immune function and deficiency</article-title>. <source>J. Immunol. Res.</source>
<volume>14</volume>, <fpage>164309</fpage> PMID:<?supplied-pmid 25309931?><pub-id pub-id-type="pmid">25309931</pub-id></mixed-citation></ref><ref id="BST-47-1757C123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Raoof</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Sumi</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Sursal</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Junger</surname><given-names>W.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Circulating mitochondrial DAMPs cause inflammatory responses to injury</article-title>. <source>Nature</source>
<volume>464</volume>, <fpage>104</fpage>&#x02013;<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1038/nature08780</pub-id><pub-id pub-id-type="pmid">20203610</pub-id></mixed-citation></ref><ref id="BST-47-1757C124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Crother</surname><given-names>T.R.</given-names></name>, <name name-style="western"><surname>Karlin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Dagvadorj</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chiba</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2012</year>) <article-title>Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis</article-title>. <source>Immunity</source>
<volume>36</volume>, <fpage>401</fpage>&#x02013;<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2012.01.009</pub-id><pub-id pub-id-type="pmid">22342844</pub-id></mixed-citation></ref><ref id="BST-47-1757C125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jo</surname><given-names>E.K.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J.K.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>D.M.</given-names></name> and <name name-style="western"><surname>Sasakawa</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>) <article-title>Molecular mechanisms regulating NLRP3 inflammasome activation</article-title>. <source>Cell. Mol. Immunol.</source>
<volume>132</volume>, <fpage>148</fpage>&#x02013;<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1038/cmi.2015.95</pub-id></mixed-citation></ref><ref id="BST-47-1757C126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Vazquez</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Moghaddas</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hoppel</surname><given-names>C.L.</given-names></name> and <name name-style="western"><surname>Lesnefsky</surname><given-names>E.J.</given-names></name></person-group> (<year>2003</year>) <article-title>Production of reactive oxygen species by mitochondria: central role of complex III</article-title>. <source>J. Biol. Chem.</source>
<volume>278</volume>, <fpage>36027</fpage>&#x02013;<lpage>36031</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M304854200</pub-id><pub-id pub-id-type="pmid">12840017</pub-id></mixed-citation></ref><ref id="BST-47-1757C127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Won</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Son</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Yu</surname><given-names>J.W.</given-names></name></person-group> (<year>2015</year>) <article-title>Rotenone-induced impairment of mitochondrial electron transport chain confers a selective priming signal for NLRP3 inflammasome activation</article-title>. <source>J. Biol. Chem.</source>
<volume>290</volume>, <fpage>27425</fpage>&#x02013;<lpage>27437</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M115.667063</pub-id><pub-id pub-id-type="pmid">26416893</pub-id></mixed-citation></ref><ref id="BST-47-1757C128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Widdrington</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gomez-Duran</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Steyn</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Pyle</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ruchaud-Sparagano</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Mitochondrial DNA depletion induces innate immune dysfunction rescued by IFN-&#x003b3;</article-title>. <source>J. Allergy Clin. Immunol.</source>
<volume>140</volume>, <fpage>1461</fpage>&#x02013;<lpage>1464</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaci.2017.04.048</pub-id><pub-id pub-id-type="pmid">28629747</pub-id></mixed-citation></ref><ref id="BST-47-1757C129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canta</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pozzi</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Carozzi</surname><given-names>V.</given-names></name></person-group> (<year>2015</year>) <article-title>Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy</article-title>. <source>Toxics</source>
<volume>3</volume>, <fpage>198</fpage>&#x02013;<lpage>223</lpage>
<pub-id pub-id-type="doi">10.3390/toxics3020198</pub-id><pub-id pub-id-type="pmid">29056658</pub-id></mixed-citation></ref><ref id="BST-47-1757C130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Couch</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Higuchi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>) <article-title>Mitochondrial dysfunction induced by sertraline, an antidepressant agent</article-title>. <source>Toxicol. Sci.</source>
<volume>127</volume>, <fpage>582</fpage>&#x02013;<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1093/toxsci/kfs100</pub-id><pub-id pub-id-type="pmid">22387747</pub-id></mixed-citation></ref><ref id="BST-47-1757C131"><label>131</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Neyts</surname><given-names>J.</given-names></name></person-group> (<year>2009</year>) <chapter-title>Antiviral agents acting as DNA or RNA chain terminators</chapter-title> In <source>Handbook of Experimental Pharmacology</source> (<person-group person-group-type="editor"><name name-style="western"><surname>Kr&#x000e4;usslich</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Bartenschlager</surname><given-names>R.</given-names></name></person-group> eds), pp. <fpage>53</fpage>-<lpage>84</lpage>, <publisher-name>Springer-Verlag</publisher-name>, <publisher-loc>Berlin</publisher-loc></mixed-citation></ref><ref id="BST-47-1757C132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Matthews-Davis</surname><given-names>N.</given-names></name> and <name name-style="western"><surname>Reardon</surname><given-names>J.</given-names></name></person-group> (<year>1994</year>) <article-title>Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>38</volume>, <fpage>2743</fpage>&#x02013;<lpage>2749</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.38.12.2743</pub-id><pub-id pub-id-type="pmid">7695256</pub-id></mixed-citation></ref><ref id="BST-47-1757C133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>B.</given-names></name> and <name name-style="western"><surname>Copeland</surname><given-names>W.</given-names></name></person-group> (<year>2003</year>) <article-title>Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>2</volume>, <fpage>812</fpage>&#x02013;<lpage>822</lpage>
<pub-id pub-id-type="doi">10.1038/nrd1201</pub-id><pub-id pub-id-type="pmid">14526384</pub-id></mixed-citation></ref><ref id="BST-47-1757C134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laberge</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Adler</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>DeMaria</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Mechtouf</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Teachenor</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Cardin</surname><given-names>G.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Mitochondrial DNA damage induces apoptosis in senescent cells</article-title>. <source>Cell Death Dis.</source>
<volume>4</volume>, <fpage>e727</fpage>&#x02013;<lpage>e727</lpage>
<pub-id pub-id-type="doi">10.1038/cddis.2013.199</pub-id><pub-id pub-id-type="pmid">23868060</pub-id></mixed-citation></ref><ref id="BST-47-1757C135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benbrik</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Chariot</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Bonavaud</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ammi-Sa&#x00131;&#x000a8;d</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Frisdal</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Rey</surname><given-names>C.</given-names></name><etal>et al.</etal></person-group> (<year>1997</year>) <article-title>Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells</article-title>. <source>J. Neurol. Sci.</source>
<volume>149</volume>, <fpage>19</fpage>&#x02013;<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-510X(97)05376-8</pub-id><pub-id pub-id-type="pmid">9168161</pub-id></mixed-citation></ref><ref id="BST-47-1757C136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Papoian</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Louie</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>D.P.</given-names></name>, <name name-style="western"><surname>Payne</surname><given-names>R.M.</given-names></name><etal>et al.</etal></person-group> (<year>1991</year>) <article-title>Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts</article-title>. <source>Lab. Invest.</source>
<volume>65</volume>, <fpage>228</fpage>&#x02013;<lpage>236</lpage><pub-id pub-id-type="pmid">1715447</pub-id></mixed-citation></ref><ref id="BST-47-1757C137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan-Zhou</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Sommadossi</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Darley-Usmar</surname><given-names>V.</given-names></name></person-group> (<year>2000</year>) <article-title>Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>44</volume>, <fpage>496</fpage>&#x02013;<lpage>503</lpage>
<pub-id pub-id-type="doi">10.1128/AAC.44.3.496-503.2000</pub-id><pub-id pub-id-type="pmid">10681309</pub-id></mixed-citation></ref><ref id="BST-47-1757C138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chabi</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Adhihetty</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Ljubicic</surname><given-names>V.</given-names></name> and <name name-style="western"><surname>Hood</surname><given-names>H.</given-names></name></person-group> (<year>2005</year>) <article-title>How is mitochondrial biogenesis affected in mitochondrial disease?</article-title>
<source>Med. Sci. Sports Exerc.</source>
<volume>37</volume>, <fpage>2102</fpage>&#x02013;<lpage>2110</lpage>
<pub-id pub-id-type="doi">10.1249/01.mss.0000177426.68149.83</pub-id><pub-id pub-id-type="pmid">16331136</pub-id></mixed-citation></ref><ref id="BST-47-1757C139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnaudo</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Shanske</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>DiMauro</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Schon</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Moraes</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Schon</surname><given-names>E.</given-names></name><etal>et al.</etal></person-group> (<year>1991</year>) <article-title>Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy</article-title>. <source>Lancet</source>
<volume>3377</volume>, <fpage>508</fpage>&#x02013;<lpage>510</lpage>
<pub-id pub-id-type="doi">10.1016/0140-6736(91)91294-5</pub-id></mixed-citation></ref><ref id="BST-47-1757C140"><label>140</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>M&#x000fc;ller</surname><given-names>B.</given-names></name> and <name name-style="western"><surname>Kr&#x000e4;usslic</surname><given-names>H.G.</given-names></name></person-group> (<year>2009</year>) <chapter-title>Antiviral strategies</chapter-title> In <source>Handbook of Experimental Pharmacology</source> (<person-group person-group-type="editor"><name name-style="western"><surname>Kr&#x000e4;usslich</surname><given-names>H.G.</given-names></name> and <name name-style="western"><surname>Bartenschlager</surname><given-names>R.</given-names></name></person-group> eds), pp. <fpage>1</fpage>&#x02013;<lpage>24</lpage>, <publisher-name>Springer-Verlag</publisher-name>, <publisher-loc>Berlin, Heidelberg</publisher-loc></mixed-citation></ref><ref id="BST-47-1757C141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkman</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Smeitink</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Romijn</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Reiss</surname><given-names>P.</given-names></name></person-group> (<year>1999</year>) <article-title>Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy</article-title>. <source>Lancet</source>
<volume>354</volume>, <fpage>1112</fpage>&#x02013;<lpage>1115</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(99)06102-4</pub-id><pub-id pub-id-type="pmid">10509516</pub-id></mixed-citation></ref><ref id="BST-47-1757C142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lleonart</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Grodzicki</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Graifer</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Lyakhovich</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>) <article-title>Mitochondrial dysfunction and potential anticancer therapy</article-title>. <source>Med. Res. Rev.</source>
<volume>37</volume>, <fpage>1275</fpage>&#x02013;<lpage>1298</lpage>
<pub-id pub-id-type="doi">10.1002/med.21459</pub-id><pub-id pub-id-type="pmid">28682452</pub-id></mixed-citation></ref><ref id="BST-47-1757C143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hangas</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Aasumets</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kek&#x000e4;l&#x000e4;inen</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Palohein&#x000e4;</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pohjoism&#x000e4;ki</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Gerhold</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2018</year>) <article-title>Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of topoisomerase 2</article-title>. <source>Nucleic Acids Res.</source>
<volume>46</volume>, <fpage>9625</fpage>&#x02013;<lpage>9636</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gky793</pub-id><pub-id pub-id-type="pmid">30169847</pub-id></mixed-citation></ref><ref id="BST-47-1757C144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>J.W.</given-names></name>, <name name-style="western"><surname>Claire</surname><given-names>D.C.</given-names></name>, <name name-style="western"><surname>Weissig</surname><given-names>V.</given-names></name> and <name name-style="western"><surname>Rowe</surname><given-names>T.C.</given-names></name></person-group> (<year>1996</year>) <article-title>Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells</article-title>. <source>Mol. Pharmacol.</source>
<volume>50</volume>, <fpage>1178</fpage>&#x02013;<lpage>1188</lpage><pub-id pub-id-type="pmid">8913349</pub-id></mixed-citation></ref><ref id="BST-47-1757C145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalghatgi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Spina</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Costello</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Liesa</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Morones-Ramirez</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Slomovic</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells</article-title>. <source>Sci. Transl. Med.</source>
<volume>5</volume>, <fpage>192ra85</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3006055</pub-id></mixed-citation></ref><ref id="BST-47-1757C146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Darkin-Rattray</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Neims</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Rowe</surname><given-names>T.</given-names></name></person-group> (<year>1993</year>) <article-title>4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells</article-title>. <source>J. Cell. Biochem.</source>
<volume>51</volume>, <fpage>165</fpage>&#x02013;<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.240510208</pub-id><pub-id pub-id-type="pmid">8440750</pub-id></mixed-citation></ref><ref id="BST-47-1757C147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Sui</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><etal>et al.</etal></person-group> (<year>2016</year>) <article-title>Apoptotic transition of senescent cells accompanied with mitochondrial hyper-function</article-title>. <source>Oncotarget</source>
<volume>7</volume>, <fpage>28286</fpage>&#x02013;<lpage>28300</lpage><pub-id pub-id-type="pmid">27056883</pub-id></mixed-citation></ref><ref id="BST-47-1757C148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dasari</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Tchounwou</surname><given-names>P.B.</given-names></name></person-group> (<year>2014</year>) <article-title>Cisplatin in cancer therapy: molecular mechanisms of action</article-title>. <source>Eur. J. Pharmacol.</source>
<volume>740</volume>, <fpage>364</fpage>&#x02013;<lpage>378</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2014.07.025</pub-id><pub-id pub-id-type="pmid">25058905</pub-id></mixed-citation></ref><ref id="BST-47-1757C149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ta</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Espeset</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Podratz</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Windebank</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>) <article-title>Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding</article-title>. <source>Neurotoxicology</source>
<volume>27</volume>, <fpage>992</fpage>&#x02013;<lpage>1002</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuro.2006.04.010</pub-id><pub-id pub-id-type="pmid">16797073</pub-id></mixed-citation></ref><ref id="BST-47-1757C150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marullo</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Werner</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Degtyareva</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Altavilla</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Ramalingam</surname><given-names>S.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions</article-title>. <source>PLoS ONE</source>
<volume>8</volume>, <fpage>e81162</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0081162</pub-id><pub-id pub-id-type="pmid">24260552</pub-id></mixed-citation></ref><ref id="BST-47-1757C151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crouch</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Knowels</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Stuppard</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ericson</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bielas</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Marcinek</surname><given-names>D.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects</article-title>. <source>PLoS ONE</source>
<volume>12</volume>, <fpage>e0181086</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0181086</pub-id><pub-id pub-id-type="pmid">28700655</pub-id></mixed-citation></ref><ref id="BST-47-1757C152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Astolfi</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Ghiselli</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Guaran</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Chicca</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Simoni</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Olivetto</surname><given-names>E.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation</article-title>. <source>Oncol. Rep.</source>
<volume>29</volume>, <fpage>1285</fpage>&#x02013;<lpage>1292</lpage>
<pub-id pub-id-type="doi">10.3892/or.2013.2279</pub-id><pub-id pub-id-type="pmid">23404427</pub-id></mixed-citation></ref><ref id="BST-47-1757C153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meltzer</surname><given-names>H.Y.</given-names></name></person-group> (<year>1994</year>) <article-title>An overview of the mechanism of action of clozapine</article-title>. <source>J. Clin. Psychiatry</source>
<volume>55</volume>, <fpage>47</fpage>&#x02013;<lpage>52</lpage> PMID:<?supplied-pmid 7961573?><pub-id pub-id-type="pmid">7961573</pub-id></mixed-citation></ref><ref id="BST-47-1757C154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walss-Bass</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Weintraub</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hatch</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Mintz</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Chaudhuri</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>) <article-title>Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations</article-title>. <source>Int. J. Neuropsychopharmacol.</source>
<volume>11</volume>, <fpage>1097</fpage>
<pub-id pub-id-type="doi">10.1017/S1461145708008882</pub-id><pub-id pub-id-type="pmid">18466668</pub-id></mixed-citation></ref><ref id="BST-47-1757C155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Streck</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Rezin</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Barbosa</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Assis</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Grandi</surname><given-names>E.</given-names></name> and <name name-style="western"><surname>Quevedo</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>) <article-title>Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain</article-title>. <source>Naunyn Schmiedebergs Arch. Pharmacol.</source>
<volume>376</volume>, <fpage>127</fpage>&#x02013;<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1007/s00210-007-0178-2</pub-id><pub-id pub-id-type="pmid">17673979</pub-id></mixed-citation></ref><ref id="BST-47-1757C156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chapman</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Keane</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Meldrum</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Simiand</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Vernieres</surname><given-names>J.</given-names></name></person-group> (<year>1982</year>) <article-title>Mechanism of anticonvulsant action of valproate</article-title>. <source>Prog. Neurobiol.</source>
<volume>19</volume>, <fpage>315</fpage>&#x02013;<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1016/0301-0082(82)90010-7</pub-id><pub-id pub-id-type="pmid">6134304</pub-id></mixed-citation></ref><ref id="BST-47-1757C157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ponchaut</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Van Hoof</surname><given-names>F.</given-names></name> and <name name-style="western"><surname>Veitch</surname><given-names>K.</given-names></name></person-group> (<year>1992</year>) <article-title>In vitro effects of valproate and valproate metabolites on mitochondrial oxidations</article-title>. <source>Biochem. Pharmacol.</source>
<volume>43</volume>, <fpage>2435</fpage>&#x02013;<lpage>2442</lpage>
<pub-id pub-id-type="doi">10.1016/0006-2952(92)90324-C</pub-id><pub-id pub-id-type="pmid">1610408</pub-id></mixed-citation></ref><ref id="BST-47-1757C158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sangkuhl</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>T.</given-names></name> and <name name-style="western"><surname>Altman</surname><given-names>R.</given-names></name></person-group> (<year>2009</year>) <article-title>Selective serotonin reuptake inhibitors pathway</article-title>. <source>Pharmacogenet. Genomics</source>
<volume>19</volume>, <fpage>907</fpage>&#x02013;<lpage>909</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e32833132cb</pub-id><pub-id pub-id-type="pmid">19741567</pub-id></mixed-citation></ref><ref id="BST-47-1757C159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Souza</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Polizello</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Uyemura</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Castro-Silva</surname><given-names>O.</given-names></name> and <name name-style="western"><surname>Curti</surname><given-names>C.</given-names></name></person-group> (<year>1994</year>) <article-title>Effect of fluoxetine on rat liver mitochondria</article-title>. <source>Biochem. Pharmacol.</source>
<volume>48</volume>, <fpage>535</fpage>&#x02013;<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1016/0006-2952(94)90283-6</pub-id><pub-id pub-id-type="pmid">8068040</pub-id></mixed-citation></ref><ref id="BST-47-1757C160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curti</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Mingatto</surname><given-names>F.E.</given-names></name>, <name name-style="western"><surname>Polizello</surname><given-names>A.C.</given-names></name>, <name name-style="western"><surname>Galastri</surname><given-names>L.O.</given-names></name>, <name name-style="western"><surname>Uyemura</surname><given-names>S.A.</given-names></name> and <name name-style="western"><surname>Santos</surname><given-names>A.C.</given-names></name></person-group> (<year>1999</year>) <article-title>Fluoxetine interacts with the lipid bilayer of the inner membrane in isolated rat brain mitochondria, inhibiting electron transport and F1F0-ATPase activity</article-title>. <source>Mol. Cell Biochem.</source>
<volume>199</volume>, <fpage>103</fpage>&#x02013;<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1023/A:1006912010550</pub-id><pub-id pub-id-type="pmid">10544958</pub-id></mixed-citation></ref><ref id="BST-47-1757C161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinedinst</surname><given-names>N.J.</given-names></name> and <name name-style="western"><surname>Regenold</surname><given-names>W.T.</given-names></name></person-group> (<year>2014</year>) <article-title>A mitochondrial bioenergetic basis of depression</article-title>. <source>J. Bioenerg. Biomembr.</source>
<volume>47</volume>, <fpage>155</fpage>&#x02013;<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1007/s10863-014-9584-6</pub-id><pub-id pub-id-type="pmid">25262287</pub-id></mixed-citation></ref><ref id="BST-47-1757C162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eto</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Inoue</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Ogata</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Fukuda</surname><given-names>T.</given-names></name> and <name name-style="western"><surname>Araki</surname><given-names>Y.</given-names></name></person-group> (<year>1985</year>) <article-title>Effect of tricyclic drugs on mitochondrial membrane</article-title>. <source>Acta Med. Okayama</source>
<volume>39</volume>, <fpage>289</fpage>&#x02013;<lpage>295</lpage><pub-id pub-id-type="pmid">2931948</pub-id></mixed-citation></ref><ref id="BST-47-1757C163"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Razaq</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Kendall</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Bates</surname><given-names>T.</given-names></name></person-group> (<year>2010</year>) <article-title>The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria</article-title>. <source>Neurochem. Res.</source>
<volume>36</volume>, <fpage>327</fpage>&#x02013;<lpage>338</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-010-0331-z</pub-id><pub-id pub-id-type="pmid">21120605</pub-id></mixed-citation></ref><ref id="BST-47-1757C164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katyare</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Rajan</surname><given-names>R.R.</given-names></name></person-group> (<year>1995</year>) <article-title>Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria</article-title>. <source>Comp. Biochem. Physiol. Part C: Pharmacol. Toxicol. Endocrinol.</source>
<volume>112</volume>, <fpage>353</fpage>&#x02013;<lpage>357</lpage>
<pub-id pub-id-type="doi">10.1016/0742-8413(95)02031-4</pub-id></mixed-citation></ref><ref id="BST-47-1757C165"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>La</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>2009</year>) <article-title>A comparative proteomics analysis of Rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications</article-title>. <source>J. Proteome Res.</source>
<volume>8</volume>, <fpage>3633</fpage>&#x02013;<lpage>3641</lpage>
<pub-id pub-id-type="doi">10.1021/pr800876z</pub-id><pub-id pub-id-type="pmid">19441803</pub-id></mixed-citation></ref><ref id="BST-47-1757C166"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferguson</surname><given-names>J.</given-names></name></person-group> (<year>2001</year>) <article-title>SSRI antidepressant medications</article-title>. <source>Prim. Care Companion J. Clin. Psychiatry</source>
<volume>3</volume>, <fpage>22</fpage>&#x02013;<lpage>27</lpage>
<pub-id pub-id-type="doi">10.4088/PCC.v03n0105</pub-id><pub-id pub-id-type="pmid">15014625</pub-id></mixed-citation></ref></ref-list></back></article>